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ABSTRACT 
 
GLUT4 protein is the major glucose transporter in skeletal muscle and is vital in the 
maintenance of euglycemia (17; 108). Underexpression of GLUT4 or impairement of its 
translocation from intracellular compartments to the cell surface, are linked to diminished glucose 
transport, hyperglycemia and type II diabetes (59; 61; 153). Type II diabetes can be alleviated by 
increasing GLUT4 expression (223). Previous reports have shown that overexpression of NRF-1 
and activation of CaMKII increases GLUT4 expression but the mechanisms involved have not be 
characterized (10; 173). Therefore, the objective of this thesis was to investigate the molecular 
mechanisms by which NRF-1 and CaMK II regulate GLUT4 expression in C2C12 myocytes. 
We engineered C2C12 cells that overexpressed NRF-1 in response to doxycycline (Dox) 
using a Tet-On gene expression system and assessed the effects of NRF-1 overexpression on: a) 
MEF2A, GLUT4 and δALAS proteins by western blot, and b) the binding of NRF-1 to mef2a and 
δalas genes and MEF2A to the glut4 gene, by chromatin immunoprecipitation assay (ChIP). The 
importance of MEF2A in NRF-1-induced increase in GLUT4 expression was investigated by 
silencing MEF2A expression using small interference RNA (siRNA). CaMK II was activated in 
wild-type C2C12 myocytes using 10 mM caffeine and was inhibited by 25 µM KN93. Acetylation 
of histones in the vicinity of NRF-1 and MEF2A binding sites on the mef2a and glut4 genes, 
respectively, were assessed by ChIP assay. HDAC5 nuclear export was assessed by 
immunocytochemistry and mRNA levels by qRT-PCR.  
Overexpression of NRF-1 resulted in ~3-fold increases in mef2a-bound NRF-1 and glut4 -
bound MEF2A at 6 h and 8 h post Dox treatment, respectively. MEF2A and GLUT4 proteins were 
both increased ~1.6-fold at 6 h and 18 h post Dox treatment. Silencing of MEF2A caused a marked 
downregulation of GLUT4 expression in NRF-1-overexpressing cells. The results support the 
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notion that NRF-1 overexpression increases GLUT4 expression via a transcriptional cascade 
involving NRF-1→ mef2a→ MEF2A→ glut4→ GLUT4.  
CaMK II activation with caffeine for 2 h resulted in a ~2.5-fold increase in binding of NRF-
1 to the mef2a gene 6 h after treatment, hyperacetylation of histone H3 in the vicinity of the NRF-1 
binding domain on the mef2a gene, and ~ 2-fold increase in MEF2A expression 6 h post treatment. 
Moreover, we observed ~2-fold increase in the binding of MEF2A to the glut4 gene, 
hyperacetylation of histones in the vicinity of MEF2A binding sites on the glut4 gene, significant 
nuclear export of HDAC5, and ~2.8-fold increase in GLUT4 expression 6 h post treatment. 
CaMKII inhibition with KN93 resulted in significant decreases in all the observed changes; 
indicating that CaMK II was involved in these pathways. Collectively these results support the 
notion that CaMK activation remodels chromatin to increase the binding of NRF-1 to the mef2a 
gene and MEF2A to the glut4 gene and increases their expression.  
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CHAPTER 1 
The problem and its setting 
1.1 Introduction    
 
          Type II diabetes is a non communicable metabolic disorder characterised by impaired plasma 
glucose disposal, resulting in hyperglycemia. This disease is most common among individuals who 
are physically inactive. In these individuals, the impairment in glucose transport from plasma into 
tissues, especially into muscle tissues, appears to result from a) down regulation of GLUT4, the 
insulin-sensitive glucose transporter b) the attenuation of insulin-mediated signalling cascade (162; 
174)  and c) insulin resistance due to impaired mitochondrial function (161; 177; 181). Physically 
active individuals are generally protected from type II diabetes because physical activity increases 
GLUT4 expression and translocation, and mitochondrial content (24; 43; 104; 179; 208). Because 
changes in the contents of muscle mitochondria and GLUT4 occur in parallel (10; 11), it has been 
suggested that they are initiated by the same signal and/or have common signalling intermediaries 
(10; 11; 91; 208).  
           It is now well established that mitochondrial biogenesis relies on the interplay of genes that 
are expressed from both nuclear and mitochondrial genomes. The coordinated expression of these 
genes is achieved through the action of transcription factors called nuclear respiratory factors 
(NRF)-1 and NRF-2 that belong to the cap „n‟ collar-basic leucine zipper (CNC-bZIP) proteins 
(102). The expression of the nrf-1 gene, together with the genes that depend on its expression, are 
down-regulated in patients with type II diabetes and those with a family history of the disease (161; 
177). Lately it has been shown that NRF-1 also regulates GLUT4 expression: For example, 
transgenic mice that overexpress NRF-1 have markedly elevated GLUT4 levels (10). Because the 
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NRF-1 cis element is not present on the glut4 gene, it has been hypothesised that the increase in 
GLUT4 expression in NRF-1 transgenic mice is a result of a transcriptional cascade involving 
NRF-1  mef2a  glut4. Support for this hypothesis comes from the fact that the mef2a gene has a 
NRF-1 binding site (185) and MEF2A is the key transcriptional regulator of the glut4 gene (223). 
This hypothesis implies that NRF-1 might be one of the signalling intermediaries that link GLUT4 
expression with mitochondrial biogenesis and therefore would be a suitable target for the design of 
therapeutic drugs for use in the treatment and management of type II diabetes. Since direct evidence 
for the existence of a NRF-1  mef2a  glut4 transcriptional cascade is still lacking, one of the 
aims of this project was to provide evidence for or against the existence of this transcriptional 
cascade.  
            The transcriptional activity of MEF2 factors are influenced markedly by their interaction 
with histone modifying enzymes such as class II histone deacetylases (HDACs) and histone acetyl 
transferases (HATs). HDACs remove negatively charged acetyl groups from histones which 
condense chromatin and render it less accessible to transcriptional regulators (13). Many 
researchers have shown that the presence of MEF2-HDAC complexes on regulatory elements of 
genes harbouring MEF2 binding sites is associated with repression of those genes (79; 158). Of 
note is the discovery that MEF2-HDAC complexes may be dissociated when two serine-containing 
motifs on the deacetylase are phosphorylated by calcium/calmodulin dependent protein kinase 
(CaMK) II (41; 118; 143) and once phosphorylated, the HDACs are shuttled from the nucleus to 
the cytoplasm by chaperone molecules (25; 156; 158). The nucleocytoplasmic shuttling of HDACs 
relieves HDAC-mediated repression of MEF2-dependent
 
genes and promotes association of MEF2 
with HATs (79; 237). HATs catalyze the transfer of acetyl moieties to lysine residues on histones, 
resulting in their repulsion by the negatively charged DNA (62). This process allows increased 
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access of transcription factors to binding domains on DNA and is associated with increased gene 
transcription. Indeed, there is a growing body of evidence showing that increases in the expression 
of GLUT4 and mitochondrial proteins in skeletal muscle require CaMK II activation: Firstly, 
CaMK transgenic mice have higher mitochondrial content than wild-type mice (234). Secondly, 
exercise increases GLUT4 protein levels in muscle and inhibition of CaMK II activity by KN93 
during exercise abrogated these effects (212). Thirdly, incubation of myotubes with caffeine to 
increase cytosolic calcium and activate CaMK II has also been shown to increase GLUT4 and 
mitochondrial proteins and inclusion of KN93 together with caffeine prevents these increases (172; 
173).  
             Although there is ample data which demonstrate that CaMK II is required for GLUT4 
expression, there is still no direct evidence that CaMK II activation affects events at the glut4 
promoter. Therefore this study also tested the hypothesis that CaMK II activation induces 
hyperacetylation of histones in the vicinity of the MEF2 binding site on the glut4 gene and 
increases the binding of MEF2A to the site in C2C12 myotubes. Furthermore, since activation of 
CaMK II by caffeine increases MEF2A expression (173), and the mef2a gene has one NRF-1 
binding domain (185), we further tested the hypothesis that CaMK II activation induces 
hyperacetylation of histones in the neighbourhood of the NRF-1 binding site on the mef2a gene to 
increase NRF-1 binding there.  
1.2. The objectives of this study 
 
There were two main objectives of the study: The first objective was to investigate the 
molecular mechanism by which NRF-1 regulates GLUT4 expression in C2C12 cell line. In this 
regard, we tested the hypothesis that NRF-1 regulates GLUT4 expression via a transcriptional 
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cascade involving NRF-1 mef2a  glut4. The second objective of the study was to investigate the 
molecular mechanisms by which CaMK II activation by caffeine increases GLUT4 expression in 
C2C12 myotubes. In this regard we tested the hypotheses that CaMKII activation: a) causes 
HDAC5 nuclear export, b) induces hyperacetylation of histones in the vicinity of the MEF2 binding 
site on the glut4 gene, and c) increases MEF2A binding to the glut4 gene. 
 
 
 
 
 
 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
  
9 
 
CHAPTER 2 
Literature Review 
2.1. Introduction 
   
  A review of related literature is provided in this chapter. This review starts by discussing 
several studies that have provided evidence that regular physical activity protects individuals from 
insulin resistance and type II diabetes. Next, it looks at studies that have provided the molecular 
mechanisms for protection. In this regard, studies which have shown that physical activity 
upregulates GLUT4 expression and promote mitochondrial biogenesis, are discussed. The 
molecular signals that coordinate GLUT4 expression and mitochondrial biogenesis, especially 
NRF-1 and CaMK are reviewed in detail. Lastly, the effects of CaMK II activation on a) the 
remodelling of chromatin to facilitate the binding of NRF-1 to genes that code for mitochondrial 
and MEF2 proteins and b) the binding of MEF2A to the glut4 gene, are examined.  
2.2. A comparison of the incidence of type II diabetes amongst sedentary and physically active 
individuals 
Epidemiological studies indicate that individuals who maintain regular physical activity are 
much less likely to develop type II diabetes than physically inactive persons (26; 62; 69; 86; 100; 
137; 138; 148; 150; 151). The reduction in the risk of diabetes due to physical activity is, in part, 
due to increased glucose transport capacity and improved insulin sensitivity (95; 106; 120; 169; 
189; 220).  
           A study by Helmrich et al., (86) investigated the association between leisure time physical 
activity and the risk of type II diabetes amongst 5990 male alumni from the University of 
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Pennsylvania from 1962-1976. They found that: a) leisure time physical activity, expressed as 
kilocalories expended per week in walking, stair climbing, and sports, was inversely related to the 
development of non-insulin dependent diabetes mellites (NIDDM); b) for each 500-kcal increment 
in energy expenditure, the age-adjusted risk of NIDDM was reduced by 6 %; and c) the protective 
effects of physical activity was strongest in persons at highest risk of NIDDM, i.e. people with high 
body mass index, a history of hypertension, or a family history of diabetes. Another study, “The 
Nurses Health Study” by Manson et al., (151) showed that physical activity also protects women: 
They followed 87,253 diabetic-free US women aged 34-59 years for 8 years and found that women 
who engaged in vigorous physical activity at least once per week had a 33 % lower risk of type 2 
diabetes compared to sedentary controls that did not engaged in physical activity. Similar results 
were observed in other studies (51; 101; 204).  
Type II diabetes is often preceded by a reduction in insulin sensitivity which is characterised 
by a defect in the insulin signalling pathways that may result in impaired translocation of GLUT4 to 
the cell surface (71). Many studies have investigated the relationship between physical activity and 
insulin sensitivity. For example, the “Insulin Resistance Atherosclerosis Study” by Mayer-Davis et 
al., (154) showed that both vigorous and mild activities were positively associated with insulin 
sensitivity amongst 1467 men and women of 40-69 years of age. The “British Regional Study” by 
Wannamethee et al., (229), which studied 5159 men aged 40-59 years, showed that light and 
moderate physical activities were significantly and inversely associated with serum insulin 
concentrations. Some studies have found that six weeks of training by insulin-resistant and diabetic 
patients increased insulin stimulated glucose transport by 2-fold compared to sedentary controls 
(179). Short et al., (208) also showed that 16 weeks of moderate-intensity aerobic exercise 
increased insulin sensitivity and glucose transport independent of age. In contrast, cessation of 
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physical activity for 14 days by endurance-trained runners or strength-trained weight lifters was 
associated with a decrement in insulin sensitivity.  
          Associations between physical activity, insulin sensitivity and glucose transport, have been 
shown in animal models too: For example, ten weeks of endurance training increased insulin 
sensitivity in rats (7; 189); exercise restores to normal the levels of insulin sensitivity and whole 
body glucose disposal in severely diabetic rats (39; 72; 107; 231); voluntary exercise on running 
wheels increased glucose transport capacity in rats (47; 90; 109; 192; 209); and male Sprague-
Dawley rats that swam with weights attached to their tails for 2 h a day for 5 days exhibited 87 % 
and 85 %  increases in glucose transport and insulin responsiveness, respectively, compared to 
sedentary rats; and physical activity delayed  or  prevented the onset of type II diabetes in rats 
(119).  
Collectively, these studies, showing that regular physical activity improves insulin 
sensitivity and decreases the risk of type II diabetes in humans and animals, provide the basis for 
the current advocacy of regular physical activity as a way to protect individuals from these diseases. 
However, the molecular mechanisms of protection are not fully understood.  
2.3. The mechanisms by which physical activity protects people from diabetes 
 Epidemiological data showing fewer cases of type II diabetes in individuals who are 
physically active compared to those who are sedentary have suggested that physical activity 
protects against type II diabetes. Controlled experiments employing exercise interventions in 
human and animal models have provided evidence that alterations in metabolic and gene expression 
profiles in skeletal muscle are responsible for the protective effects of exercise. In this section, two 
mechanisms by which physical activity induces protection are presented. They are: a) increase in 
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mitochondrial biogenesis and efficiency, and b) increased GLUT4 expression. The section ends by 
discussing the parallel increases in mitochondrial biogenesis and GLUT4 expression by exercise.  
 2.3.1. Mitochondrial biogenesis due to physical activity confers protection against type II 
diabetes: Skeletal muscle is endowed with mitochondria which oxidize lipids to produce ATP. 
Regular physical activity induces mitochondrial biogenesis (increases mitochondrial number, 
proteins and DNA) resulting in increased capacity for lipid oxidation and turnover (24; 83) and 
improved insulin sensitivity, i.e. it enhances the ability of endogenous insulin to decrease glucose in 
plasma by inhibiting glucose release from the liver and stimulating peripheral consumption (42; 
43). In an experiment with men and women aged 21-87 years, Short et al. (208) showed  that 16 
weeks of aerobic physical activity increased citrate synthase and cytochrome c oxidase (markers of 
mitochondrial content) by 46 % and 87 %, respectively. In the same study, insulin sensitivity was 
increased by an average of 26 % in both women and men. Others have shown that the content of 
cytochrome c oxidase was increased by 42 % and 35 % in trained and untrained healthy volunteers, 
respectively, following a moderate training program (28; 44). In the same study, insulin sensitivity 
was improved by 41 % and 49 % in the trained and untrained subjects, respectively. Mitochondrial 
ATP production rate increased by 161 % in the vastus lateralis muscle of middle-aged men and by 
170 % in elderly men after 10 days of cycling (17). Mitochondrial DNA (mtDNA) and density is 
1.5-1.8-fold higher in skeletal muscle of endurance trained athletes compared to sedentary 
individuals (184). The above reports represent only a few examples of the vast amount of data 
showing that exercise increases mitochondrial content and improve insulin sensitivity in skeletal 
muscle. 
 In contrast to regular physical activity, chronic inactivity results in a decrease in 
mitochondrial proteins and number (96), aberrant lipid handling (155) and impaired insulin 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
  
13 
 
sensitivity (24; 127). Insulin sensitivity of skeletal muscle and ATP production rates are 60 % and 
30 % lower, respectively, in chronically inactive people compared to active individuals. The 
reduction in insulin sensitivity in these people was associated with elevated intramyocellular 
triacylglycerols and their derivatives, and corresponded with decreases in mitochondrial oxidative 
capacity and mitochondrial ATP synthesis (181). There is now strong evidence that accumulation 
of fats in skeletal muscle induces insulin resistance by disrupting the insulin signalling cascade (1; 
48; 142; 149; 163; 170; 202; 203; 216). The insulin signalling cascade begins by the binding of 
insulin to the  subunit of its receptor on muscle plasma membranes. When this happens, the -
subunits, which possess tyrosine kinase activity, are activated via autophosphorylation. Activated 
insulin receptors phosphorylate and activate insulin receptor substrates (IRS) -1 and -2 on tyrosine 
residues and creates docking sites for the adaptor protein, phosphatidylinositol 3-kinase (PI3K), 
which catalyzes the phosphorylation of phophatidylinositol-4,5 bisphosphate (PIP2) to form 
phophatidylinositol-3,4,5 triphosphate (PIP3) which creates a lipid-based platform for the 
recruitment of serine/threonine kinase B (PKB) which, by a mechanism which is not fully 
characterized, induces GLUT4 translocation from the intracellular endosomes in muscle cells to the 
cell surfaces, to facilitate glucose diffusion from plasma into the muscle cells (30; 230). The ability 
of endogenous insulin to stimulate glucose uptake by the muscle is refered to as insulin sensitivity 
of the muscle. Defects in the insulin-stimulated GLUT4 translocation mechanism in the muscle 
diminish insulin sensitivity and induce insulin resistance and type II diabetes (4; 60; 65; 66). Insulin 
resistance (IR) is the condition in which normal amounts of insulin are inadequate to produce a 
normal insulin response from cells. It has been shown that impairment of mitochondrial function 
due to inactivity leads to reduction in the volume of lipids targeted for oxidation, resulting in 
accumulation of fatty acids and their metabolites such as long chain fatty acyl CoA (LCACoA), 
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diacylglycerol (DAG) and ceramide (142). Increased intracellular levels of these lipid metabolites 
have been functionally linked to impaired insulin sensitivity in skeletal muscle (202). It is now 
known that they promote phosphorylation of IRS-1 on serine residues by protein kinase C (PKC), 
thereby counteracting their tyrosine phosphorylation by the insulin receptor  subunit and inhibiting 
insulin signalling pathway. Accumulation of fats and their metabolites therefore induce insulin 
resistance in muscle, i.e. they interfere with the insulin signalling cascade and inhibit GLUT4 
translocation to plasma membrane to enhance glucose transport (24; 48). Experimental supports for 
the role of lipids in inducing insulin resistance are many: For example, infusion of lipids in rats for 
5 h increases IRS-1 serine phosphorylation by ~1.6-fold in soleus muscle (238). Moreover infusion 
of lipids for five hours has been shown to increase ceramide and LCACoA concentration, enhance 
PKC activity and reduce IRS-1 tyrosine phosphorylation and IRS-1 associated PI3K activity in 
soleus muscle. Interestingly, lipid infusion had no effect on insulin receptor tyrosine 
phosphorylation; demonstrating that the effects of lipids occur at the level of IRS-1 (64; 105; 121). 
Confirmation that lipids induce insulin resistance via serine phosphorylation of IRS-1 has come 
from experiments showing that mutation of the serine residue in IRS-1 to alanine rescues cells from 
lipid-induced insulin resistance (1).  
 Schenk & Horowitz (201) have shown that one session of exercise is sufficient to 
completely reverse fatty acid-induced impairment in insulin sensitivity. Ninety minutes of 
moderate-intensity exercise during a lipid-infusion protocol, which increased plasma lipid levels 4-
fold above basal and impaired insulin sensitivity by 30 % in sedentary controls, not only prevented 
insulin resistance but also improved insulin sensitivity by 25 % above basal levels. Skeletal muscle 
diacylglycerol and ceramide concentration were significantly lower in the exercise group compared 
to the sedentary controls. Phosphorylation and activation of cytokines that are responsible for 
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impairing insulin signalling pathway were reduced by 50 % in the exercise group compared to the 
sedentary group (170). These experiments demonstrate the effectiveness of exercise in controlling 
the accumulation FFAs metabolites that confer insulin resistance. 
 Analysis of muscle samples from young, lean, normoglycemic, but insulin resistant 
offsprings of type II diabetics revealed that insulin-stimulated glucose transport was 60 % lower in 
these offspring than in control healthy subjects and this was associated with 60 % higher 
intramuscular lipid content. Skeletal muscle mitochondrial density was lower by ~38 % in these 
offsprings. These changes were associated with ~50 % increase in IRS-1 serine phosphorylation 
and reduced tyrosine phosphorylation. Moreover, Akt, a signalling molecule in insulin signalling 
cascade, was also reduced by 60 %. These data provide insight into early defects that may be 
responsible for the development of type II diabetes and support the idea that reduction of 
mitochondrial content  predisposes offsprings of diabetic patients to intramuscular lipid 
accumulation that cause defects in insulin signalling in the muscle (163). These data further suggest 
that the reduction of mitochondrial content that results from a sedentary lifestyle may also cause 
intramuscular lipid accumulation, defects in insulin signalling, insulin resistance, and ultimately 
type II diabetes. 
 In summary, insulin resistance can be reversed by interventions that reduce the 
intramuscular contents of LCACoA, ceramide and DAGs. Bruce et al. (24) and others (170; 201) 
have shown that moderate-intensity endurance training decreases intramuscular ceramide, 
LCACoA and DAGs. The decreases in these metabolites were associated with improvement in 
insulin sensitivity and in mitochondrial fat oxidative capacity. These data clearly show that 
increased mitochondrial content due to exercise protects against insulin resistance and type II 
diabetes by increasing the capacity of the mitochondria to oxidize fats and its derivatives. 
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 2.3.2. Increased GLUT4 content by physical activity protects against type II diabetes:  
Skeletal muscle is the major site for whole body insulin-stimulated glucose disposal and is 
responsible for about 70-80 % of glucose uptake from plasma (43). As discussed before, glucose 
enters muscle cells predominantly via GLUT4 protein which resides in intracellular compartment 
vesicles but is translocated to the cell membrane to enhance glucose transport. Like insulin, 
exercise also induces GLUT4 translocation to cell membranes: Hansen et al., (81) showed that after 
3.5 h of exercise, there was a 2-fold increase in plasma membrane GLUT4 and a similar increase in 
glucose transport in rat muscle, compared to controls. Kennedy et al., (120) showed that 45-60 min 
of cycling at 60-70 % VO2max caused plasma membrane GLUT4 protein to increase to the same 
extent (~71-74 %) in the vastus lateralis muscles of diabetic patients and non diabetic subjects. 
King et al., (122) showed that a single bout of exercise increased plasma membrane GLUT4 content 
in severely insulin resistant obese Zucker rats (fa/fa) by ~ 2.2-fold  and this was accompanied by ~ 
4.1-fold increase in glucose transport, compared to controls. Collectively, these results show that 
unlike insulin, acute exercise effectively translocates GLUT4 to the cell surface and increases 
glucose transport in insulin resistant and diabetic animals. Goodyear et al (71) also reported that in 
rats, insulin injection increased tyrosine phosphorylation of IRS-1 and IRS/PI3K, whereas 
contraction had no effect. Addition of wortmannin, an inhibitor of PI3K, significantly reduced 
glucose transport and GLUT4 translocation in insulin-stimulated muscle whereas addition of higher 
a concentration of wortmannin (1µM) had no effect on exercise-induced GLUT4 translocation and 
glucose transport. Lund et al., (144) further showed that PKB activity was increased ~4-fold with 
insulin stimulation but exercise had no effect. Collectively, these observations indicate that GLUT4 
translocation by exercise is mediated by a signalling pathway which is distinct from that induced by 
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insulin and suggest that insulin and exercise probably use different pools of GLUT4 transporters 
(38).  
 Many researchers have shown that exercise increases insulin sensitivity: Hansen et al., (81) 
showed that insulin sensitivity increased by 60 % in rats that were exercised for 3.5 h compared to 
the sedentary controls. In humans, Short et al., (208) have shown that 4 months of exercise training 
in elderly people result in 26 % increase in insulin sensitivity. In young people, insulin sensitivity 
increases after a single session of exercise but in middle and old age people, the increase in insulin 
sensitivity only appears after a few sessions. The increase in insulin sensitivity by exercise 
disappears 3-6 days after session of exercise (87).  
 A conspicuous increase in glucose transport and GLUT4 protein expression occur in 
skeletal muscle in response to exercise training. This observation is supported by a large body of 
evidence from different studies (33; 61; 85; 92; 97). For example, Houmard et al., (99) have 
reported ~1.8-fold increase in GLUT4 protein concentration in middle- aged men after 14 weeks of 
exercise training from the vastus lateralis muscle. Seven days of cycle ergometer training was 
reported to increase GLUT4 ~2.0-2.8-fold in the vestus lateralis muscle (78; 98). Physical training 
increases GLUT-4 protein by 40 % and mRNA by 52 % in a long term aerobic physical training 
accompanied by 26 % improvement in insulin sensitivity in aged subjects and in patients with type 
II diabetes (167; 205; 208). In a study where diabetic patients performed one-legged ergometer 
bicycle training for 9 weeks (6 days/week; 30 min/day), GLUT4 mRNA and protein increased by 
30 % and 22 %, respectively on the trained leg compared to the untrained leg. GLUT4 protein 
increased by ~74 % and 71 % and glucose transport by ~47 %  and 28 % in type II diabetes patients 
and normal healthy individuals respectively in response to exercise training (45; 120; 225). In many 
studies, diabetics tend to show more pronounced increases in GLUT4 due to exercise compared to 
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non-diabetic people. In insulin resistant obese Zucker rats, exercise also increased insulin 
sensitivity primarily by increasing GLUT4 protein content (36; 37; 61). In one study using obese 
Zucker rats, seven weeks of training induced a ~2.3-fold increase in GLUT4 compared to sedentary 
rats and was accompanied by  ~4.5-fold glucose transport (122). 
  Regular exercise increases GLUT4 expression and insulin sensitivity in parallel (129). In a 
study involving rats, it was found that 2 hours of swimming per day for 5 days increased GLUT4 
protein concentration and insulin sensitivity by 87 % and 85 %, respectively, relative to controls. 
Forty two hours after training, GLUT4 protein concentration and insulin sensitivity were still higher 
by 52 % and 51 % respectively in muscle from trained rats compared to controls. GLUT4 protein 
concentration and insulin sensitivity in trained muscle returned to sedentary control level within the 
90 h after training. These results show that changes in insulin sensitivity during detraining is 
directly related to muscle GLUT4 protein content (119). The increases in GLUT4 content and 
glucose transport capacity seen after long-duration low-intensity exercise also occur in high-
intensity short-duration intermittent exercise in rats (222) and in humans (120; 208).          
 Skeletal muscle of type II diabetic and insulin resistant rats and mice is characterised by 
deficiency in insulin stimulated recruitment of GLUT4 to the cell surface (196; 243). In these 
animals, specific overexpression of GLUT4 restores insulin sensitivity to normal. Insulin stimulated 
glucose transport is impaired in diabetic obese db/db mice despite unaltered GLUT4 expression 
(126); indicating that the translocation of GLUT4 to the cell surface is the main cause. 
Overexpression of GLUT4 in these mice normalizes oral glucose tolerance and increases insulin 
sensitivity (68). In streptozotocin-induced diabetic rats, skeletal muscle GLUT4 mRNA and protein 
are reduced concomitantly with whole body insulin sensitivity (21; 29; 167). Overexpression of 
GLUT4 in skeletal muscle also improves insulin action and reduces basal plasma glucose levels in 
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these rats (134). These data demonstrate that impaired insulin action in these diabetic rats arise 
from reduced GLUT4 expression. As mentioned earlier, several studies have shown that exercise 
can increase GLUT4 content and glucose uptake in individuals who are insulin resistant or in type 
II diabetics. Collectively, results from all the above studies are consistant with the notion that 
increased GLUT4 content, whether by overexpression, as is the case with GLUT4 transgenic 
animals or by means of exercise training, prevents hyperglycemia and enhances whole-body 
glucose disposal (103).  
Exercise can also increase glucose transport and GLUT4 translocation through adenosine 
monophosphate (AMP)-activated protein kinase (AMPK) activation (93). AMPK is a signalling 
intermediate that is increased during moderate to -intensity exercise which reduces the ATP and 
phosphocreatine concentration in muscle cells and   increases AMP. In rats, activation of AMPKα2 
by AICAR has been shown to increase skeletal muscle glucose disposal by increasing the translocation 
of GLUT4 to the sarcolemma (117). In transgenic mice expressing the dominant negative mutant of 
AMPKα2, there is a significant impairement of glucose uptake in response to exercise. These 
observations have led researchers to conclude that AMPK is also a suitable target for anti-diabetic 
drugs (84; 117). 
 In summary, impaired insulin-stimulated GLUT4 expression and translocation in muscle 
cells are important causes of insulin resistance and type II diabetes. Since exercise increases 
GLUT4 content, GLUT4 translocation to the plasma membrane, and glucose uptake in type II 
diabetes patients--thereby improving whole body glucose disposal and insulin sensitivity--it is 
therefore an important therapeutic modality for insulin resistance and type II diabetes (95). Hence 
studies such as this one, which seek to elucidate the molecular mechanisms involved in exercise-
induced upregulation of GLUT4 content, could identify molecular targets for drugs to treat type II 
diabetes and insulin resistance.  
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  2.3.3. Physical activity induces mitochondrial biogenesis and increases GLUT4 
expression in parallel:  Many studies have shown that stimuli that increase mitochondrial 
biogenesis also increase GLUT4 expression (10; 11; 19; 57; 91; 208). For example, Short et al., 
(208) has shown that 16 weeks of moderate aerobic exercise intensity increases GLUT4 protein and 
mRNA by ~30-50 % and mitochondrial biogenesis by ~45-76 % simultaneously. Expression of 
muscle-specific inactive form of AMPK results in abrogation of the increases in both GLUT4 and 
mitochondrial proteins by exercise, indicating that AMPK may signal their regulation during 
exercise (32; 63; 186; 191; 232). CaMKII activation by exercise or caffeine has been shown to 
increase both GLUT4 and mitochondrial proteins in animal and cell culture models, respectively 
(57; 172; 173; 211; 212). It is well established that mitochondrial biogenesis is regulated by NRF-1 
(46; 133; 199; 226). As expected, overexpression of NRF-1 in transgenic mice results in augmented 
mitochondrial proliferation (10). Intriguingly, NRF-1 transgenic mice also have increased GLUT4 
expression (10).These observations have prompted us to speculate that there is cross talk between 
the signalling pathways for mitochondrial biogenesis and GLUT4 expression.   
2.4. The role of NRF-1 in regulating mitochondrial and GLUT4 expressions. 
  This section reviews the role of NRF-1 in regulating mitochondrial biogenesis and in the 
expression of MEF2 transcription factors; and how these impact on GLUT4 expression. 
           2.4.1. NRF-1 is one of the transcription factors that regulate mitochondrial biogenesis: 
NRF-1 is a transcriptional factor that regulates mitochondrial biogenesis (53; 73). The biogenesis of 
mitochondria involves the interaction of two genomes, namely those located in the nucleus and 
those housed in the mitochondria. Mitochondrial genome codes for 13 respiratory chain 
polypeptides, 2 ribosomal RNAs and 22 transfer RNAs. The nuclear genome encodes all the rest of 
the proteins necessary for a complete maintenance and expression of mitochondria. NRF-1, and 
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other transcription factors, acts on nuclear genes that express the proteins involved in heme 
biosynthesis, oxidative phosphorylation, mitochondrial gene transcription and replication, protein 
import into the mitochondria, and numerous respiratory chain subunits that are involved with 
cellular respiration (53). Regulation of the expression of this multitude of genes by these 
transcription factors culminates in a well coordinated program of activities in the nucleus and in the 
mitochondria that result in mitochondrial biogenesis. Because the mitochondrion is crucial in 
generating ATP from substrates, the activity of NRF-1 in cells must match the ATP demand in the 
cells. Therefore, NRF-1 can be regarded as a critical component of the energy sensing machinery in 
mammalian cells which converts physiological signals that arise during conditions of energy 
demand, e.g. physical activity, into improved ability for energy generation (135).           
  Sequence analysis shows that NRF-1 is a putative bZIP transcriptional factor and has a gene 
map locus at 7q32 in humans which spans approximately 65 kb with 12 exons and 11 introns (73). 
NRF-1 was initially known as an activator of cytochrome c expression but was later found to 
regulate many genes encoding subunits from all five respiratory complexes (46; 52; 199). It 
functions together with other transcription factors including NRF-2, stimulating protein -1(Sp1) and 
MEF-2; and transcriptional coactivators such as peroxisome proliferator-activated receptor gamma 
coactivator-1 (PGC-1α) alpha (125; 160; 215). NRF-1 binds as a homodimer to the GC-rich 
palindromic sequence (T/C)GCGCA(C/T)GCGC(A/G) and forms a strong affinity bond with less 
tolerance for non compliance (164; 185).  
         NRF-1 is amongst the seven identified transcription factors that are frequently found in the 
proximal promoters of ubiquitously expressed genes (56). Chromatin immunoprecipitation (ChIP) 
and ChIP-on-chip assays have shown that of the 13000 human promoters surveyed, 691 genes 
were occupied by NRF-1 in living cells and the majority of those genes were involved in 
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mitochondrial biogenesis and metabolism (27; 188). A few of the NRF-1 target genes that code 
for key mitochondrial proteins are discussed here illustrate the role that NRF-1 plays in 
mitochondrial biogenesis: Firstly, for mitochondrial DNA (mtDNA) to replicate, a nuclear-
encoded transcriptional factor called mitochondrial transcription factor A (TFAM) is required. 
TFAM expression requires the binding of NRF-1 on the tfam gene (35). Choi et al. (35) showed 
that when NRF-1 sites on the tfam promoter were mutated, approximately 90 % tfam activity was 
lost. Since NRF-1 controls tfam expression to regulate mtDNA, it can therefore be concluded that 
NRF-1 regulates both nuclear and mitochondrial genome resulting in complete and normal 
mitochondrial functions. Secondly, NRF-1 also regulates the expression of δ-aminolevulinic acid 
synthase (δALAS), a rate-limiting enzyme in the synthesis of heme (135). NRF-1 binding sites 
are present in the δalas gene and are highly conserved in human, mouse and rat species (22; 32). 
δALAS catalyses the condensation of glycine and succinyl-CoA to form 5-aminolevulinate, and 
first step in heme synthesis. Heme is part of the respiratory cytochromes that play an important 
role in the transfer of electrons from fuels to oxygen in the electron transport chain to generate 
ATP. The activity of δALAS determines the respiratory capacity of the mitochondria. Thirdly, 
another important mitochondrial enzyme that relies on NRF-1 activity is cytochrome c oxidase 
(COX). COX is a transmembrane protein found in the inner membranes of the mitochondria of 
eukaryotic cells. It is the terminal enzyme in the electron transport chain which binds molecular 
oxygen and reduces it to water. This enzyme is responsible for over 90 % of the oxygen 
consumption by living organisms. It also pumps protons across the mitochondrial membrane and 
contributes to the proton gradient that exists across the inner mitochondrial membrane. It is a 
multi-subunit holoenzyme consisting 13 polypeptides; ten of which are encoded in the nucleus 
and their expression controlled by NRF-1 (46). Genomic sequence analysis show that the 
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promoter regions of some skeletal muscle-specific COX isoforms, such as COX6A, COX7A and 
COX8, which are nuclear encoded, lack NRF cis elements but have conserved MEF2A binding 
sites (133; 185; 228; 238). It has now been shown by many independent researchers that NRF-1 
coordinates the expression of these COX isoforms by binding to the mef2a gene to increase 
MEF2A expression and MEF2A then binds to these COX isoforms (46; 133; 185; 228). These 
studies suggest that the coordinated expression of many proteins that form part of the 
mitochondria involves a transcriptional cascade involving NRF-1  mef2a  nuclear gene. 
 2.4.2. Does NRF-1 play a role in regulating GLUT4 expression? Baar et al., (10) showed 
that transgenic mice that overexpressed NRF-1 had elevated levels of mitochondrial proteins as 
well as GLUT4. The increase in GLUT4 was not expected because NRF-1 has no binding sites on 
the glut4 gene. The mechanism through which NRF-1 up-regulates GLUT4 expression has not been 
studied and forms one of the aims of this study. What is known is that glut4 gene expression is 
regulated by the binding of MEF2A/D heterodimer together with the GLUT4 enhancing factor 
(GEF) to their respective sites on the glut4 promoter (162; 223). It is quite conceivable that NRF-1 
regulates GLUT4 expression indirectly via MEF2. As discussed in section 2.4.1, there is growing 
body of evidence that suggest a cordial relationship between NRF-1 and MEF2A whereby NRF-1 
regulates the expression of MEF2A and MEF2A in turn regulates other genes (10; 133; 165; 185; 
228). An example of this relationship was discussed in the case of COX genes. Since glut4 gene is a 
target of MEF2A (223), it is logical to hypothesise that the increase in GLUT4 expression reported 
in NRF-1 transgenic mice is due to a transcriptional cascade involving NRF-1  mef2a  glut4. 
This hypothesis would also suggest that NRF-1 is responsible for coordinating the increase in 
GLUT4 expression and mitochondrial biogenesis in response to exercise. However, direct evidence 
to support this hypothesis is still lacking.  
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 2.4.3. Evidence that NRF-1 might play a role in exercise-induced increase in the 
expression of GLUT4 and mitochondrial proteins: Although it has been consistently reported that 
both GLUT4 and mitochondrial proteins are upregulated in parallel by stimuli such as exercise, the 
signal that coordinates their parallel upregulation has not been identified. In NRF-1 transgenic 
mice, GLUT4, MEF2A and mitochondrial proteins are all increased (10). Mimicking the effects of 
exercise with caffeine in myotubes increased NRF-1 binding to mitochondrial genes and 
upregulated the expression of MEF2A, GLUT4 and selected mitochondrial proteins (172; 173).The 
fact that NRF-1 controls the mef2a gene to induce the expression of respiratory subunits (185), 
suggests that NRF-1 may also induce the expression of GLUT4 since GLUT4 is also regulated by  
MEF2A  (223). Therefore, it may be hypothesized that the simultaneous increases in both GLUT4 
and mitochondrial proteins by exercise may be due to the actions of NRF-1 on mef2a. However 
evidence for this hypothesis is still lacking. 
2.5. The impact of CaMK II activation on chromatin remodelling, mitochondrial biogenesis 
and GLUT4 expression. 
 CaMK II has been implicated in the regulation of gene expression. For example, it 
phosphorylates HDACs and causes their export out of the nucleus. HDACs suppress gene 
transcription and their export from the nucleus favours the action of HATs, which favour gene 
transcription. In this section the mode of action of CaMK II is described and the mechanism by 
which it regulates GLUT4 expression and mitochondrial biogenesis is discussed.   
 2.5.1. CaMK II regulates GLUT4 & mitochondrial protein expression: CaMK II is a 
calcium/calmodulin (Ca
2+
/CaM) dependent protein kinase which mediates a myriad of 
physiological responses. It is a holoenzyme consisting of 8 to 12 subunits (206); each subunit 
consisting of a conserved N-terminal regulatory domain and a C-terminal domain. The regulatory 
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domain is formed by an auto-inhibitory domain, a calmodulin binding domain and numerous 
autophosphorylation threonine sites. Binding of Ca
2+
/CaM to the CaM binding domain is presumed 
to disrupt the auto-inhibitory interactions and allow substrates and ATP to gain access to the 
catalytic site. This interaction results in auto-phosphorylation of threonine which increases its 
sensitivity to Ca
2+
/CaM by ~1000-fold (178).  
 In skeletal muscle, CaMK II modulates gene transcription and various signalling pathways 
that enable muscle to adapt to stimuli such as exercise (57; 178). CaMK II is not active at rest but 
its activity is triggered by increases in free calcium concentration that is displayed during muscle 
contraction (178). With regard to  GLUT4 regulation, CaMK II activation by exercise has been 
shown to result in increased GLUT4 and MEF2A protein expressions in rats (211; 212). Incubation 
of L6 myotubes with caffeine, an agent that raises cytosolic calcium levels in an exercise-like 
manner, also increases GLUT4 and MEF2A proteins (172).  
CaMK II has also been reported to be involved in mitochondrial biogenesis. Using L6 
myotubes, Ojuka et al., (173) showed that activation of CaMK II increased mitochondrial markers 
such as δALAS, COX-1 and cytochrome c. Wright et al., (233) also showed that incubation of 
isolated rat epitrochlearis muscle with caffeine, to activate CaMK II resulted in augmented levels of 
mitochondrial mRNA, and proteins such δALAS, COX and citrate synthase. The strongest evidence 
implicating CaMK in mitochondrial biogenesis has come from Wu et al. (234) who used muscle 
specific CaMKIV transgenic mice. Skeletal muscles from these mice had increased levels of 
proteins for mitochondrial DNA replication, transcription, fatty acid metabolism, and electron 
transport.  
  2.5.2. CaMK II activation influences mef2a and nrf-1 gene transcription through 
acetylation: Chromatin, which is composed of DNA wound around histone proteins, has a dynamic 
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structure which influences gene transcription. A compact structure retards transcription whereas a 
relaxed configuration favours gene expression. In general, acetylation of histones by HATs relaxes 
chromatin (217) and enables transcriptional
 
factors (e.g. NRF-1 or MEF2A) to have access to their 
respective binding domains on
 
the DNA. Conversely, deacetylation of histones by HDACs 
generally represses genes (23; 31; 213; 218). HDACs also repress MEF2-dependent genes by 
associating with MEF2 transcription factors to form gene-repressing complexes
 
on MEF2 binding 
sites (79; 159). External signals, such as stress or exercise activate CaMK II which phosphorylate 
two serine-containing motifs on HDACs within the HDAC/MEF2 complex and induces HDAC 
nuclear export by chaparones. HDAC nuclear export relieves HDAC-mediated repression of 
MEF2-dependent
 
genes (156; 159) and favours increased HAT activity. HATs, such as p300,
 
also 
acetylate MEF2 to increase binding and transcriptional activity (198). The binding activity of NRF-
1 has also been shown to be increased by posttranslational acetylation (110) and phosphorylation 
(77). Our group has previously shown that activation of CaMK II by caffeine in L6 myotubes 
increases NRF-1 binding to δalas gene by 90 % (172).  
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CHAPTER 3 
Description and Optimization of Experimental Procedures 
3.1. Introduction 
 
This study was conducted to investigate the molecular mechanism by which a) NRF-1 
regulates GLUT4 expression and b) CaMK II activation brings about a coordinated expression of 
GLUT4 protein in skeletal muscle. The studies were conducted using the C2C12 muscle cell line. 
In this chapter, a justification for the use of the cell culture model is provided, the experimental 
procedures and protocols used to answer the various experimental questions are described, and 
evidence showing that these procedures and protocols were optimized is presented. 
3.2. Justification for the use of a cell culture model 
C2C12 cells, a skeletal muscle cell line of mouse origin, have been used widely in various 
studies and have proved to be easy to work with. They serve as an excellent model system for 
investigating complex biochemical adaptations that occur in skeletal muscle. Like skeletal muscle 
they have a well formed mitochondria and differentiate into multinucleated myotubes. They also 
exhibit most, if not all, the principles of mechano-biochemical adaptations associated with 
contractility (123; 166; 182; 207). Cell culture experiments are more convenient than in vivo 
experiments in establishing molecular pathways that arise from a specific stimulus because they 
are conducted in an isolated system which removes the influences of the brain, hormones and 
other physiological interferences. In human and animal models, exercise triggers many 
physiological and biochemical responses at the same time, which makes it difficult to isolate the 
mechanism responsible for the changes observed.  
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For the part of our studies, in which we characterized the role played by NRF-1 in 
regulating GLUT4 expression, we found it quite easy to induce forced overexpression of NRF-1 in 
C2C12 myoblasts using Tet-On gene expression system. In the studies where the role of CaMK II 
activation in coordinating the expression of GLUT4 was investigated, CaMK II activation was 
easily accomplished by incubating the cells with caffeine (172; 173; 233). 
 3.3. General cell culture protocol 
 
          C2C12 myocytes were maintained at 37 
o
C in 5 % CO2 on 100 mm collagen-coated plastic 
petri-dishes containing DMEM (Dulbecco‟s modified eagles medium) supplemented with 10 mM 
creatine, 100 μU/ml streptomycin, 100 μU/ml penicillin, 0.25 μg/ml fungizone and 10 % heat-
inactivated fetal calf or bovine serum. Cells were maintained in continuous passage by 
trypsinization of sub-confluent cultures with 0.25 % trypsin versene. Myoblast differentiation was 
induced by introduction of medium containing 2 % heat-inactivated horse serum once myocytes 
were ~80 % confluent. Cells were kept in this medium for 8-13 days until myotubes were well 
formed. 
3.4. Development of the Tet-On gene expression system in C2C12 myocytes 
      To develop a system that controls the expression of NRF-1, we employed the Tet-On gene 
expression system (Clonotech, Paulo, CA) that is based on the use of the E. coli tetracycline-
resistance operon (74). Two plasmids were inserted into C2C12 myocytes to form a double stable 
cell line: The first, pTet-On, produces a regulatory protein called reverse tetracycline 
transactivator (rtTA) and the second plasmid, pTRE2Hyg, into which mouse NRF-1 cDNA was 
cloned, is the response plasmid which expresses NRF-1 when rtTA binds to its tetracycline 
response element (TRE) in the presence of the tetracycline derivative doxycycline (Dox). Because 
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the plasmid lacks strong enhancer elements, no expression of NRF-1 is expected in the absence of 
bound rtTA and Dox.  
 
 
Figure 3.1: An overview of the stages in the development of the double stable C2C12-Tet-On-NRF-1 cell line. The 
first plasmid to be introduced to C2C12 myoblasts was pTet-On. The C2C12-Tet-On resistant clones were selected 
using G418 antibiotic (Neomycin). The second plasmid, pTREHyg-NRF-1, which is the response plasmid was 
introduced to the C2C12-Tet-On clones. Selection of C2C12-Tet-On-NRF-1 resistant clone was achieved using 
hygromycin antibiotic. Western blot was used to determine the clones that had high induction of NRF-1 when treated 
with Dox but with low background. These clones were used as the C2C12-Tet-On-NRF-1 cell line for all subsequent 
experiments. 
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           To develop the Tet-On system in C2C12 cells we generated the mouse NRF-1 cDNA, 
cloned cDNA into the pTRE2Hyg and transfected Tet-On and pTRE2Hyg-NRF-1 plasmids into 
C2C12 myotubes (Fig. 3.1). These procedures are described in detail below: 
  3.4.1. NRF-1 cDNA generation: Total RNA was isolated using Trizol (Ambion, Austin, 
TX) according to manufacturer‟s protocol. Briefly, a triceps muscle was excised from mouse and 
stored in a cryovial in liquid nitrogen. The frozen tissue was disrupted using a pestle and mortar 
in liquid nitrogen and 1 ml of Trizol reagent was added to the homogenized tissue sample. Tissue 
homogenates were mixed, incubated for 5 min at room temperature, centrifuged at 12000 x g for 
10 min at 4 
o
C and the supernatant transferred to a fresh clean tube. Two hundred l of 
chloroform was added to the supernatant and incubated at room temperature for 15 min and 
centrifugated at 12000 x g for 10 min at 4
 o
C. The aqueous phase was transferred to a fresh tube 
containing 500 l of isopropanol and the mixture vortexed for 10 s and incubated for 10 min at 
room temperature. This was centrifuged at 12000 x g for 8 min at 20 
o
C and the supernatant 
discarded. The pellet, containing RNA, was washed with ethanol, air dried, and re-suspended in 
20 l nuclease-free water. RNA concentration and optical density at 260 and 280 nm was 
measured in triplicates using 1 μl of RNA in a Nanodrop ND 100 spectrophotometer (Nanodrop 
Technology, Wilmington, DE, USA). RNA was accepted as pure from contamination when the 
260/280 nm ratio was between 1.9 and 2.1. The integrity of RNA was verified as follows: 3 μg of 
RNA was diluted in a 10 l buffer containing 6 % glycerol, 1 % MOPS, 2 M formaldehyde, 0.5 
% formamide and bromophenol blue. The mixure was heated at 55 
o
C for 15 min and separated 
by electrophoresis on a 1 % agarose gel containing 1 x MOPS, 0.66 M formaldehyde and 35 μg 
ethidium bromide. RNA was visualised under UV and deemed usable (undegraded) if the 28S and 
18S ribosomal bands were observed intact.  
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Primers for the NRF-1 cDNA which amplify a 1.74 kb section of the coding region of the 
mouse NRF-1 cDNA from position 161 to 1901 bp (Gen Bank™ accession no. NM_010938) are: 
Forward primer: 5‟-GTT GGATCC CTC TCA CCC ATT G -3‟ (Position 161-182; BamH1 
restriction sites underlined). Reverse primer: 5‟- CCA AGTCGAC GAG ACT TAA TTC C-3‟ 
(Position 1881– 1901; Sal1 restriction sites underlined). Primers for the NRF-1 cDNA were 
designed to contain BamH1 and Sal1 restriction sites to permit cloning of the transcripts into 
pTRE2Hyg and are present in the multiple cloning site of pTRE2Hyg. Real Time-Polymerase 
Chain Reaction (RT-PCR) was performed using a Qiagen OneStep RT-PCR Kit as per 
manufacturer‟s protocol (Valencia, CA). Briefly, each reaction contained a cocktail consisting of 
400 μM dNTPs, 2.5 mM MgCl2, 10 units of RNase inhibitor, 1 x RT-PCR buffer, 2 μl Qiagen 
OneStep RT-PCR enzyme mix for reverse transcription (Omniscript and Sensiscript 
transcriptases) and HotStarTaq DNA polymerase, 0.8 μΜ forward and reverse primers and 2 μg 
RNA template. The RT-PCR reaction consisted of 30 min of reverse transcription at 50 
o
C, and 
15 min of PCR reactions at 95 
o
C using HotStarTaq DNA polymerase which simultaneously 
inactivates the reverse transcriptases. RT-PCR step cycling was done as follows: 35 cycles of 
amplification (1 min denaturing at 94
 o
C, 1 min annealing at 70 
o
C, and 1 min of extension at 72 
o
C) and 1 cycle of 10 min final extension at 72
 o
C. The amplified NRF-1 cDNA from RT-PCR 
was run on 0.5 % agarose gel. It migrated at ~1.74 kb as predicted. Shown below are: a) the 
tabulated RT-PCR conditions used to generate the mouse NRF-1 cDNA (Table 3.1) and agarose 
gel of the amplified NRF-1 cDNA (Figure 3.2). 
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Table 3.1. RT-PCR Thermal cycle conditions 
Conditions Reaction time Temperature Enzyme used 
Reverse 
transcription 
30 min 50
 o
C Omniscript & Sensiscript Reverse 
transcriptases 
Initial PCR 
activation step 
15 min 95
 o
C HotStarTaq DNA polymerase. 
 
                                 
 
 
 
 
 
 
Figure 3.2: Mouse NRF-1 cDNA from biceps and triceps muscles. M represents molecular size marker. The NRF-1 
cDNA migrated at the expected 1.74 kb after electrophoresis. 
 
           In order to verify that the amplified cDNA contained a correct NRF-1 nucleotide 
sequence, a dideoxy sequencing procedure using the Applied Biosystems Big Dye Terminator 
v3.1 Cycle sequencing kit was performed as described in the manufacture‟s protocol (Applied 
Biosystems, Foster City, CA, USA). Briefly, the generated NRF-1 cDNA was used as template in 
four separate DNA amplification reactions containing 1.1 μl terminator premix (consisting of 
dNTPs and one of the four dideoxyribonucleoside triphosphates (ddNTPs) in a ratio of 100:1), 2.9 
l Bioline Half dye, 50 ng template and 1 μl of 5 μM primer and deionized water to a final 
volume of 10 μl using Applied Biosystems GeneAmp PCR System9700 (Applied Biosystems, 
Foster City, CA, USA). PCR was initiated by 1 cycle of 1 min denaturing at 96 
o
C, 20 s of 
annealing at 50 
o
C and 4 min of extension at 60 
o
C followed by 25 cycles of 10 s denaturing at  96 
1.74 kb  
NRF-1 
cDNA 
kb 
10 
 
 
 
3 
 
 
2 
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1 
 
 
 
     M      Biceps  Triceps 
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o
C, 20 s of annealing at 50 
o
C  and 4 min of extension at 60 
o
C. Denaturing produced a single 
stranded DNA which was hybridized to a synthetic deoxyribonucleotide primer during the 
annealing phase. When a ddNTP is added at the position of the corresponding normal dNTPs 
during PCR, chain termination occurs because ddNTPs lacks a hydroxyl group to facilitate chain 
elongation. Therefore, the reaction mixture would contain a mixture of prematurely terminated 
chains ending at every occurrence of each ddNTPs. The PCR product thus generated was cleaned 
up using the Sigma Sephadex G-50 columns, spun at 3200 rpm for 2 min and eluted with 20 l 
distilled water. The ddNTP-generated fragments were electrophoresed on a DNA capillary 
sequencer genetic analyser (Applied Biosystems 3130 Genetic analyser) as recommended by the 
manufacturer (Applied Biosystems, Bedford, MA). The fragments produced during PCR are of 
different sizes and carry one of the four colour dyes. The colour and size of each fragment was 
detected using a laser beam and the data collected by computer software which generated the 
chromatographs from which the sequence of nucleotides on the sequenced template DNA (NRF-1 
cDNA) was determined. The sequenced DNA template was then compared with the posted 
genomic bank mouse NRF-1 cDNA sequence, NM_010938, (NCBI, Pubmed) and found to be 
homologous (See Figure 3.3). The sequenced-verified NRF-1 cDNA was subsequently cloned 
into the pTRE2Hyg plasmid.  
  
 Seq       CACCTCCACAGCCTGGCCATCCATGGTGACTGCGCTGTCCGATATCCTGGTGGTCACTGG   99 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Genbank   CACCTCCACAGCCTGGCCATCCATGGTGACTGCGCTGTCCGATATCCTGGTGGTCACTGG   1661 
 
Seq       GGCCATGGCCACCTGCACCGGCCCGTTGCCCTGGGCGAGGCTGGTTACCACAGTCTGGTA   159 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Genbank   GGCCATGGCCACCTGCACCGGCCCGTTGCCCTGGGCGAGGCTGGTTACCACAGTCTGGTA   1601 
 
Seq       CATGCTCACAGGTATCTGGACCAGGCCATTAGCATCTTGGACTCCAGTAAGTGCTCCGAC   218 
          |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Genbank   CATGCTCACAGGGATCTGGACCAGGCCATTAGCATCTTGGACTCCAGTAAGTGCTCCGAC   1541 
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Figure 3.3: Illustration of the sequenced mouse NRF-1 cDNA as aligned with the Genbank, mouse NRF-1 
gene, NM_010938. Seq. refers to the sequenced NRF-1 cDNA, whereas the Genbank represents the NCBI gene bank 
sequence, NRF-1, NM_010938. This sequence depicts just a small section of the 1.7 kb NRF-1 gene that was aligned 
against in NCBI gene bank and found to be homologous. The NRF-1 cDNA was subsequently cloned to the 
pTRE2Hyg.  
 
  3.4.2. Transformation and amplification of pTRE2Hyg plasmids: pTRE2Hyg was used as 
the carrier for NRF-1 cDNA. It is a Tet-On response plasmid which is controlled by CMV promoter 
and a Tet response element (TRE). pTRE2Hyg was transformed in competent DH5α cells by the 
method described by Ausubel et al., (9). Briefly, 50 ng of pTRE2Hyg was added into 100 l of 
DH5α competent cells and gently mixed. The mixture was incubated on ice for 30 min and heat-
shocked for 2 min at 37 
oC. Nine hundrend μl SOC medium (2 % bactotryptone, 0.5 % yeast 
extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 + 20 mM glucose) medium was 
added to each tube and incubated at 37 
oC for 30 min. Ten μl of the transformation mixture was 
plated onto SOB agar plates (2 % bactotryptone, 0.5 % yeast extract, 10 mM NaCl, 2.5 mM KCl, 
10 mM MgCl2, 10 mM MgSO4 + 1.5 % agar) containing 100 μg/ml ampicillin and 100 μg/ml 
hygromycin antibiotics. Isolatable colonies were formed after overnight incubation at 37 C. When 
competent cells without any DNA (negative control) were plated on SOB agar plates with 100 
μg/ml ampicillin and 100 μg/ml hygromycin antibiotics and incubating for 12-14 h at 37 C, no 
colonies were observed. Colonies were picked using a sterilized toothpick and used to inoculate 5 
ml SOC culture medium containing 100 μg/ml ampicillin and 100 μg/ml hygromycin and grown for 
approximately 16 h at 37 
o
C with shaking. A 1 ml aliquot of this culture was used to inoculate 100 
ml of SOC medium which was incubated for another 16 h at 37 C with shaking. Cells were 
pelleted from the medium by centrifugation at 12,000 x g for 30 s at 4 
o
C in a microfuge. Plasmids 
were isolated from the pellets using the alkaline lysis method (9) with minor modifications as 
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follows: the pellet containing cells were re-suspended in 100 μl ice-cold solution containing 50 mM 
glucose, 25 mM Tris-HCl, 10 mM EDTA (pH 8.0) by vigorous vortexing. Two hundred l of 
freshly prepared solution containing 0.2 M NaOH and 1 % SDS was added to the 100 l of re-
suspended cells, mixed, incubated on ice and 150 μl of 3 M potassium acetate (pH 5.5) added. The 
tube was inverted gently for 10 s to disperse the solution through the viscous bacterial lysate, 
incubated on ice for 5 min, and centrifuged at 12000 x g for 5 min at 4 
o
C. The supernatant 
containing the plasmids was transferred to a new tube. An equal volume of phenol: chloroform was 
added and mixed by vortexing and the mixture centrifuged at 12000 x g for 5 min at 4 
o
C in a 
microfuge. The supernatant containing the plasmids was transferred into a fresh tube. Plasmid DNA 
was precipitated in 2 volumes of 100 % ethanol at room temperature for 10 min and then 
centrifuged at 12000 x g at 4 
o
C on a microfuge. The supernatant was gently removed by aspiration 
and the plasmid DNA pellet rinsed in 70 % ethanol. Following centrifugation, the supernatant 
containing water and ethanol was discarded and the pellet was allowed to dry for 10 min before it 
was resuspended in 20 μl DNAse free water containing pancreatic RNAse (20 μg/ml). The plasmid 
(pTRE2Hyg) was verified by enzymatic digestion with Xho1 which produces 1.5 kb and 3.75 kb 
fragments as expected. An agarose gel of the Xho1 restriction digest is shown below in figure 3.4. 
 
Figure 3.4: Agarose gel showing fragments of pTRE2Hyg after restriction digests with Xho1.  According to the 
vector construction map the observed 1.74 kb and 3.7 kb fragments are expected. 
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3.4.3. Cloning of the NRF-1 cDNA to the pTRE2Hyg vector: NRF-1-cDNA was 
directly cloned to the BamH1 and Sal1 sites in the multiple cloning sites of the pTRE2Hyg.  
pTRE2Hyg was linearised by BamHI and Sal1 and then treated with calf intestine phosphatase 
(CIP). Briefly, the CIP reaction composed of 500 ng pTRE2Hyg, 1 x CIP buffer and CIP enzyme 
at a concentration of 0.01 u/µl. The reaction mixture was incubated at 37 
o
C for 30 min after 
which a fresh 0.01 u/μl CIP enzyme was added and incubated for additional 30 min. A “stop” 
buffer was added to end the CIP reaction and the plasmids extracted using phenol: cholorform 
method. To precipitate pTRE2Hyg, 0.5 volume of 7.5 M ammonium acetate (pH 5.5) followed by 
2 volumes of 100 % ethanol were added to the final aqueous phase. pTRE2Hyg pellet was 
washed with 70 % ethanol and resuspended in 20 μl DNase free water. Ligation of NRF-1 insert 
to the pTRE2Hyg vector was carried out using T4 DNA ligase (promega). The ligation mixture, 
consisting of 400 ng vector (pTRE2Hyg), 100 ng for the insert (NRF-1 cDNA), 1 unit T4 DNA 
ligase and 1 x ligase buffer, was mixed gently and incubated at 15
 o
C for 16 h. The vector/insert is 
shown diagrammatically in figure below.  
 
Figure 3.5: Vector construction of pTRE2Hyg depicts the multiple cloning sites where the mouse NRF-1 cDNA 
was cloned. The CMV promoter is shown downstream the Tetracycline response element (TRE). The two Xho1 
restriction sites, which produce fragments of 1.74 kb and 3.75 kb, are also shown.  
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The ligation mixture was then transformed into DH5  competent cells as described in 
section 3.4.2. Alkaline lysis, followed by Xho1 restriction digestion and agarose gel electrophoresis 
were used to identify clones that had taken up the pTRE2Hyg-NRF-1 cDNA vector. In figure 3.6 
below, lanes 1 and 3 show the undigested pTRE2Hyg-NRF-1 positive clone. Lane 2 shows a 
pTRE2Hyg-NRF-1 positive clone after digestion with Xho1 which contains the expected 5.3 kb and 
1.74 kb fragments. Lane 4 indicates a clone that did not produce the expected fragments after 
digestion with Xho1 and hence was disregarded.        
       
                 
Figure 3.6: Restriction digests of various clones to identify those containing pTRE2Hyg-NRF-1 construct. Clones 
were digested with Xho1 and separated on 0.5 % agarose gel. Lane M, represent molecular weight marker, lanes 1 and 
3 represent the undigested plasmid. Lane 2 represents the positive clone which exhibited the 5.3 kb fragment 
representing the pTRE2Hyg and the 1.74 kb representing the fragment for NRF-1 cDNA. Lane 4 represents a clone that 
did not produce the expected sizes for the pTRE2Hyg-NRF-1 when digested with Xho1.   
  
3.4.4. Generation of Tet-On plasmids. The other plasmid which is a constituent of the Tet-
On gene expression system kit is the Tet-On plasmid (figure 3.7) which is 7.4 kb in size. This 
plasmid is known as the regulatory plasmid since it produces the 37 kb reverse tetracycline-
controlled transactivator protein (rtTA) consisting of a reverse Tet repressor (rTetR) protein fused 
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to the Herpes simplex virus VP16 domain (which is required by the pTRE2Hyg response plasmid 
for gene activation). The rtTA binds to the TRE on pTRE2Hyg-NRF-1 to activate gene 
transcription only in the presence of Dox. The vector construction map for the Tet-On plasmid is 
shown below in figure 3.7. Note that this plasmid contains neomycin and ampicillin resistance 
genes which permit selection of cells that have taken up the plasmid. 
 
       
Figure 3.7: Illustration of the Tet-On plasmid. The Tet-On plasmid is the regulatory plasmid that produces the 
rtTA protein (reverse tetracycline controlled transcriptional activator) which binds on to the response plasmid in the 
presence of doxycycline; resulting in gene activation. 
 
           The Tet-on plasmid was amplified by transformation into competent DH5α cells, cultured 
and verified as described in section 3.4.2 with minor modifications as follows: The pTet-On 
plasmid is reported to be a low copy number plasmid, and has a very low plasmid yield upon 
culturing (74; 236). To enhance plasmid yield during culturing, we added 170 μg/ml of 
chloramphenicol in the growth medium and incubated for 14 h. The plasmid was verified by 
restriction digests using Xho1 and HindIII restriction enzymes. Figure 3.8 below shows that upon 
restriction digestion the expected 0.9, 1.5, 2.2, and 2.9 kb bands (Clontech, Paulo, CA) were 
observed after electrophoresis.  
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Figure 3.8: Verification of the presence of the Tet-On plasmid. M: The 1 kb marker. The different bands are 
restriction digests with Xho1 & HindIII to produce the expected 0.9, 1.5, 2.2 and 2.9 kb fragments. 
 
 3.4.5. Production of stable Tet-On C2C12 myocytes: C2C12 myoblasts were allowed to 
grow to 70-90 % confluence and were transfected with 4 μg pTet-On vector (Clontech, Paulo, 
CA) using cationic liposomes (Lipofectamine, Life Technologies, Inc.). Lipofectamine (Life 
Technologies, Inc.) transfection into C2C12 myotubes in one well of a 6-well plate was done as 
follows: 4 μg DNA (Tet-On) was diluted into 250 μl Opti-MEM and mixed gently and allowed to 
stand at room temperature for 5 min. Ten µl of Lipofectamine was also diluted into 250 μl Opti-
MEM, mixed gently and allowed to incubate for 5 min at room temperature. The diluted DNA 
and Lipofectamine were mixed together and allowed to incubate for 25 min at room temperature 
to allow DNA-Lipofectamine complexes to form. After incubation, the mixture was added to 
plated cells in a 6-well plate. Two days after transfection, cells were transferred into a 10 cm 
diameter cell culture dish and allowed to grow to a density of ~2.0 x 10
5 
cell/plate. After 24 h 
growth in a 10 cm culture dish, Neomycin (G418) antibiotic was added to the culture to a 
concentration of 500 μg/ml and used to select stably transfected C2C12-Tet-On cells. Neomycin 
was a choice antibiotic since the Tet-On plasmid contains a Neomycin resistance gene. 
Neomycin-resistant clones were isolated using cloning cylinders (Sigma) and plated sequentially 
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in 96, 24 and 6-well plates and then finally to 10 cm plates where they were cultured for ~2 weeks 
until there was ~2.0 x 10
5 
cell/plate. Thereafter cells were harvested and stored at -80 
o
C in 
cryotubes until they were needed.   
 Each cryotube of frozen C2C12-Tet-On cells was revived in a 10 cm culture dish, grown 
to 70-90 % confluency, and transfected with 4 μg of pTRE2Hyg-NRF-1 vector construct using 
Lipofectamine as described above. Twenty four hours post transfection, 400 μg/ml hygromycin 
was added to the culture to select clones that had taken up the vector. The pTRE2Hyg-NRF-1 
contains the hygromycin resistance gene which allows for selection of cells that have taken up the 
plasmid. These clones, which are referred to here as double stable C2C12-Tet-On-NRF-1 cells 
were cultured in medium for 2 weeks until they had been sufficiently amplified. The clones were 
cultured in the presence or absence of Dox and its NRF-1 content was assessed by western blot. 
Approximately 60 clones were tested and clones that were not responsive to Dox and those with 
high NRF-1 levels in the absence of Dox (figure 3.9A) were discarded. Only clones that 
expressed low levels of NRF-1 in the absence of Dox and high NRF-1 under 1 μg/ml Dox 
treatment were selected (Fig 3.9B), amplified and used for  subsequent experiments.  
 
Figure 3.9: Identification of appropriate C2C12-Tet-On-NRF-1 clones for use in experiments.  Western blot was 
performed to identify C2C12-Tet-On-NRF-1 clones that had high NRF-1 induction upon Dox treatment and low 
background. A is a representative western blots from a rejected clone: It shows a clone with a high NRF-1 background 
and poor response to Dox. B is a blot from a clone with low NRF-1 content in the absence of Dox and high NRF-1 
induction with Dox. Such clone was accepted and used in subsequent experiments. 
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  3.4.6. Experiments performed with the C2C12-Tet-On-NRF-1 cell line: The double stable 
C2C12-Tet-On-NRF-1 cell line was used to study the effects of NRF-1 overexpression on the 
contents of: a) NRF-1, GLUT4, MEF2A, δALAS and α-tubulin using convectional western 
blotting,  b) mef2a and δalas promoter-bound NRF-1, and c) glut4 promoter-bound MEF2A. The 
effects of silencing MEF2A expression on the variables described in (a-c) above were also studied 
in these C2C12-Tet-On-NRF-1 cells to determine if the effects of NRF-1 overexpression occur via 
MEF2A. Details of all the protocols used in silencing MEF2A are described in sections 3.5; 3.7; 3.9 
and 3.11. 
3.5. Silencing MEF2A expression by small interference RNA   
To test the hypothesis that NRF-1 regulates GLUT4 expression via MEF2A, we silenced 
MEF2A expression in Dox-treated C2C12-Tet-On-NRF-1 myotubes using small interference RNA 
(siRNA) which targeted MEF2A mRNA.  
3.5.1. siRNA technology: The small interference RNA (siRNA) technology involves 
introduction of a double stranded RNA to a cell to induce a homology-dependent degradation of its 
own cognate mRNA (2; 50). The MEF2-siRNA (Santa Cruz) which was used in this experiment is 
a pool of 3 target-specific 20-25 nucleotides designed to knock down MEF2A mRNA, in a process 
called small interfering RNA (siRNA). The introduction of this MEF2- siRNA triggers the 
assembly of endoribonuclease-containing complexes known as RNA-induced silencing complexes 
(RISCs), which unwind the double stranded siRNA and promote base pairing interactions between 
the siRNA anti-sense strand and complementary mRNA. The bound mRNA is cleaved and 
degraded, resulting in gene silencing (2; 50; 67; 219).   
         3.5.2. Transfection protocol: A 20-80 pmol duplex MEF2A-siRNA was diluted with 100 μl 
DMEM and incubated for 5 min at room temperature. Five μl Lipofectamine (Life Technologies, 
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Inc.) was also diluted in DMEM and incubated at room temperature for 5 min. Both the diluted 
MEF2A-siRNA and Lipofectamine were mixed gently together with a pipette and incubated for 25 
min at room temperature. The MEF2A-siRNA-Lipofectamine complexes formed were overlaid 
onto cells and incubated for 12 h. After 12 h of transfection, the medium was then aspirated and the 
cell washed. The medium was replaced with a fresh normal growth medium containing serum and 
the cells were further incubated for 48 h and used for western blots.  
 3.5.3. Optimization of MEF2A-siRNA protocol: C2C12-Tet-On-NRF-1 cells were allowed 
to form myotubes in 6-well plates and 1 μg/ml Dox was added to initiate NRF-1 overexpression. 
Twelve hr after Dox treatment was initiated 30, 60 or 90 pmols of MEF2A-siRNA(sc-35895; Santa 
Cruz, CA, U.S.A) or 50 pmol of control siRNA (sc-37007; Santa Cruz, CA, U.S.A) which does not 
degrade mRNA, were transfected (see section 3.5.2) into myotubes to assess the optimal quantity 
needed to silence MEF2A expression. Transfected myotubes were cultured for 60 h in the presence 
of Dox and conventional western blotting (see Section 3.7.3) was used to verify MEF2A protein 
content. Figure 3.10 is a typical result.  
 
 
Figure 3.10: A western blot showing the effectiveness of siRNA-MEF2A on native MEF2A protein. Myotubes 
were treated with varying amounts of the siRNA-MEF2A to establish the optimum concentration to silence wild type 
MEF2A. Note that α-tubulin was not degraded by the MEF2A-siRNA or control-siRNA. 
 
 For all subsequent MEF2A silencing experiments, C2C12-Tet-On-NRF-1 myotubes were 
treated with 1 μg/ml Dox and incubated for 12 h and then transfected with 60 pmol of MEF2A-
siRNA or 50 pmol of control siRNA, incubated for a further 60 h in the presence of 1 μg/ml Dox, 
harvested and the protein content assayed by conventional western blot.  
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 3.6. CaMK II activation in C2C12 myotubes 
 
 In previous studies, Ojuka and co-workers showed that GLUT4 and MEF2A contents in 
muscle were increased when CaMK II activity was increased in L6 myotubes in culture (172; 173). 
In these studies, CaMK II was activated by incubation of myotubes in medium containing caffeine, 
an agent which induces Ca
2+
 release from the sarcoplasmic reticulum (SR) and increases cytosolic 
calcium levels. Because NRF-1 has been shown to upregulate the expression of both MEF2A and 
GLUT4, we investigated the role that NRF-1 might play in the caffeine-induced increases in 
MEF2A and GLUT4 expression in cultured myotubes. 
 Well differentiated C2C12 myotubes were incubated in serum-free medium for ~12 h before 
incubation in medium containing 10 mM
 
caffeine (Sigma) in the presence or absence of 10 µM 
dantrolene (a compound that inhibits
 
Ca
2+
 release from the SR) or 25 µM KN93 (CaMK II 
inhibitor) (Sigma) for 2 h.  After treatment, myotubes were harvested and assayed for: a) NRF-1 
binding to mef2a and δalas genes, b) acetylation of the NRF-1 binding site on mef2a and δalas 
promoters, c) MEF2A binding to the glut4 gene, d) acetylation of the MEF2A binding site on the 
glut4 promoter, e) GLUT4 and MEF2A expression, and f) HDAC5 trafficking between the nucleus 
and cytosol. Detailed protocols of the above assays are presented in sections 3.7-3.11.  
3.7. Protein assays  
 
 After treatments of C2C12-Tet-On-NRF-1 cells with Dox (Section 3.4.5) or C2C12 
myotubes with caffeine (Section 3.6) were completed, myotubes were washed twice with ice-cold 
PBS containing 1 x complete protease inhibitors (Roche). Total cellular proteins (Crude extracts), 
cytosolic proteins or nuclear proteins were extracted by the methods described below: 
3.7.1. Crude extracts: Myotubes were scraped loose from the plates in 300 l of RIPA 
buffer (56 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1 % SDS, 1 % Triton-X100, 10 
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mM Na4P2O4, 20 mM NaF, 0.15 μM okadaic acid, 4 mM Na3VO4, 1 x complete protease 
inhibitors). The cells were then transferred to clean eppendorf tubes, incubated for 20 min on ice 
and then sonicated for 5 s. The homogenate was centrifuged at 10,000 rpm for 10 min at 4 °C, the 
supernatant (the crude extract) collected, and the protein concentration measured using the Bradford 
assay method. 
3.7.2. Nuclear and cytosolic fractions: After washing myotubes twice with
 
ice-cold PBS, 
300 µl of homogenization buffer (10 mM
 
Tris, 1 mM EDTA, 5 mM MgCl2, 1.4 M sucrose, 10 mM 
Na4P2O4, 20 mM NaF, 0.15 µM okadaic acid, 4 mM Na3VO4, 1 x complete
 
protease inhibitor, 30 
µM MG132, pH 7.4) was then added and cells were scraped loose from the plate and homogenized
 
with a Dounce homogenizer. The homogenate was centrifuged at
 
600 x g for 10 min at 4 °C and the 
supernatant, containing the
 
crude cytosolic fraction, was centrifuged a second time (same speed for 
5 min) to produce the final cytosolic extract.
 
The pellet, containing nuclei, was washed in 300 µl 
homogenization
 
buffer, centrifuged as above, and resuspended in 75 µl
 
of nuclear extraction buffer 
(25 % glycerol, 0.2 mM EDTA, 15 mM MgCl2, 20 mM HEPES, 450 mM NaCl, 0.5 % Triton X-
100, 100 mM KCl,
 
25 µM MG132, 4 mM Na3VO4, 20 mM NaF, 1.5 µM okadaic
 
acid, 10 mM 
Na4P2O7, 1 x complete protease inhibitors) and sonicated on ice for 5 s. After centrifugation at 600 
x g for 5 min, the supernatant, containing the nuclear extract, was collected.
 
Protein concentrations 
of the extracts were measured using the Bradford method as follows: Five microliters  of the 
extracted protein and 95 μl of water were added to 900 μl of Bradford reagent consisting (0.02 % 
coomassie brilliant blue G250, 4.75 % ethanol, 8.5 % phosphoric acid) and incubated for 10 min 
and the optical density (OD)  measured at 595 nm. Bovine serum albumin (BSA) was used to make 
a standard curve from which the concentration of proteins in the extracts was deduced.  
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         To determine whether the extraction protocol
 
was effective in separating the cytosolic from 
the nuclear proteins, the activity
 
of lactate dehydrogenase (LDH), a cytosolic protein, and the
 
contents of α-tubulin (cytosolic protein) and histone H3 (nuclear protein) were measured in both 
extracts. LDH activity was measured
 
spectrophotometrically by assessing the rate at which NADH 
was
 
oxidized to NAD
+
 in an LDH-catalyzed reaction that is coupled
 
to the conversion of pyruvate 
to lactate. 
Pyruvate             LDH                   Lactate 
NADH                                        NAD
+
 + H
+
 
  Fifteen µg of cytosolic or nuclear extracts was added to a 1 ml of reaction
 
buffer [50 mM 
Tris (pH 7.5), 4 mM EDTA, 2 mM pyruvate, and 0.14 mM NADH] and the absorbance measured at 
340 nm every 12 sec for ~1 min. The
 
contents of α-tubulin and histone H3 proteins in the nuclear 
and cytosolic extracts were measured by
 
western blot (Section 3.7.3). Figure 3.11A. and 3.11 B, 
showing typical results from these measurements indicate that our extraction protocol effectively 
separated cytosolic and nuclear proteins.
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Figure 3.11: Separation of nuclear and cytosolic cell compartments. A: Lactate dehydrogenase (LDH) activity in 
cytosolic and nuclear extracts. LDH activity is evident in the cytosolic fraction but absent in the nuclear fraction. B: α-
tubulin (a cytosolic protein) is detectable in the cytosolic fraction but not in the nuclear fraction, whereas histone H3 (a 
nuclear protein) is enriched in the nuclear fraction but absent in the cytosolic fraction. Collectively, these control 
experiments show that the nuclear extraction protocol was effective.  
 
 3.7.3. Western blots: Crude extracts were solubilised in 2 x Laemmli sample buffer (250 
mM Tris-HCl pH 6.8, 2 % glycerol, 10 % SDS, 0.01 % of Bromophenol blue and  5 % 
mercaptoethanol), heated at 95 
o
C for 1-5 min and proteins separated by size using SDS PAGE. A 
kaleidoscope precision standard marker (Bio-Rad, Hercules, CA) was used to indicate the size of 
the proteins of interest. Proteins from SDS-PAGE were transferred to polyvinylidene diflouride 
(PVDF) membrane (Amersham, Cape Town, South Africa) in a transfer buffer (25 mM Tris-HCl, 
192 mM glycine and 20 % methanol; 4 
o
C ) at 90 mA overnight or 180 mA for 2 h. Membranes 
were blocked in 5 % non-fat dry milk or 5 % BSA (Sigma, St Louis, MA) dissolved in 1x PBS-T 
for 1 h at room temperature or overnight at 4 
o
C and thereafter incubated with antibodies against 
NRF-1, MEF2A, GLUT4, ALAS, or α-tubulin overnight at 4 oC.  Dilutions and buffers used for 
the antibodies used are summarized in Table 3.2. After washing the membranes for 3 x 7 min in 
PBS-T, they were incubated for 2 h at room temperature with appropriate HRP-conjugated 
secondary antibody (Dako, Carpinteria, CA). Membranes were washed for 2 x 7 min in PBS-T 
followed by 1x 7 min in PBS, incubated for 2-5 min in enhanced chemiluminescence (ECL) 
solution (Amersham, Cape Town, South Africa) and exposed to film (Kodak) for 20 to 60 min and 
the film developed using the protocol prescribed by the manufactures. The film was scanned using 
UN-SCAN-IT gel 6.1 software (Silk scientific, Orem, USA) and the density of signals from 
MEF2A, GLUT4 (Cell signalling, Charlottesville, VA), NRF-1 (Abcam) and ALAS (SCBT, Santa 
Cruz, CA) blots was measured and normalized to -tubulin and expressed relative to controls.  
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  3.7.4. Stripping of membranes: Where it was necessary to detect multiple proteins from the 
same PVDF membrane, sequential western blots, with different primary antibodies on the same 
membrane, were performed. The antigen-antibody interactions on a membrane that had already 
been probed with one antibody was disrupted by incubation (with shaking), in a stripping buffer 
consisting of 100 mM 2-mercaptoethanol, 2 % SDS, 62.5 mM Tris-HCl pH 6.7 at 50 
o
C for 20 min 
and washed twice in either PBS-T or TBS-T at room temperature. The stripped membrane was then 
blocked as described in section 3.7.3 before incubation with another primary antibody. 
 
 Table3.2: Antibody concentration for western blots, immunocytochemistry and ChIP assay. 
 
 
All antibodies were diluted in TBS-T/PBS-T containing 1% Fat free milk (Santa Cruz antibodies) or 5% BSA (Cell 
signalling antibodies) when used for western blot; BSA = Bovine serum albumin; TBS=Tris-buffered saline; T = 
Tween20; R.T = Room temperature1
o 
= primary antibody; 2
o 
= secondary antibody; HDAC5= Histone deacetylase 5. 
 
 
 
Protein to be 
identified 
1  Antibody 1 Antibody 
incubation 
conditions 
2  Antibody 2 Antibody 
incubation 
conditions 
MEF2A Anti-MEF2A (Cell signalling) 
diluted 1:500 in TBS-T 
Overnight  
at 4 C 
Anti-rabbit diluted in 
1:10000 TBS-T) 
2 h at R.T 
GLUT4 Anti-GLUT4 (Cell signalling) 
diluted in 1:2000 in TBS-T 
Overnight  
at 4 C 
Anti-rabbit diluted in 
1:10000 TBS-T) 
2 h at R.T 
NRF-1 Anti-NRF-1 (Abcam) diluted 
1:2000 in PBS-T) 
Overnight  
at 4 C 
Anti-rabbit diluted in 
1:10000 PBS-T) 
2 h at R.T 
ALAS Anti- ALAS (Santa Cruz) 
diluted 1:500 in PBS-T) 
Overnight  
at 4 C 
Anti-goat diluted in 
1:10000 PBS-T) 
2 h at R.T 
α-TUBULIN Anti α-tubulin (Santa Cruz) 
diluted 1:500 in PBS-T) 
Overnight  
at 4 C 
Anti-mouse diluted 
in 1:10000 PBS-T) 
2 h at R.T 
MEF2A, HDAC5,  Fluorochrome conjugated 
anti-mouse and anti-rabbit 
All these antibodies were used for 
immunocytochemistry and diluted  1:200 for 1
o
 
and 2
o 
diluted 1:1000 Un
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3.8. Immunocytochemical analysis of MEF2A and HADC5 localization in C2C12 myotubes in 
response to CaMK II activation  
 In order to study the effects of CaMK II activation on MEF2A and HDAC5 trafficking, 
immunocytochemical analyses of C2C12 myotubes were performed on myotubes that were treated 
with caffeine or vehicle.  
             3.8.1. Treatment of myotubes for immunocytochemistry: Myotubes were kept in serum-
free medium for ~12 h before treatments. The treatments involved incubation in medium containing 
10 mM caffeine in the presence or absence of 10 µM dantrolene (calcium release inhibitor) or 25 
µM KN93 for 2 h.  
           3.8.2. Immunocytochemistry: Immediately after treatments as described in section 3.7.1, 
myotubes were washed in ice-cold PBS and fixed with 3:1 methanol/glacial acetic acid at –20 °C 
for 10 min. Thereafter, they were washed in PBS, blocked in 1 % BSA for 30 min, and incubated 
overnight at 4 °C with antibodies against HDAC5 (Santa Cruz) and MEF2A (Cell signalling). The 
following day, cells were washed and incubated with fluorochrome-conjugated anti-rabbit (Cy3) 
(Dianova) and goat anti-mouse (Alexa) secondary antibodies (diluted 1:1000) for 2 h at room 
temperature. Nuclei were stained using a 1:50 dilution of 0.05 µg/ml DAPI for 10 min at room 
temperature. After washing the cells, a coverslip was mounted on the cells with a solution 
consisting of 40 % glycerol, 20 % Mowiol, 8 % n-propyl gallate, and 0.2 M Tris buffer (pH 7.4). 
Subcellular location of HDAC5 and MEF2A was viewed using a Zeiss Axiovert 200M 
fluorescence microscope equipped with plan-neofluar optics set at 15 (Cy3), 10 (Alexa 488), and 1 
(DAPI) as well as an Axiocam HR charge-coupled device camera. Adobe Photoshop 7 software 
was used for image processing.  
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3.9. Chromatin immunoprecipitation (ChIP) assays  
ChIP assay was used to assess the amount of: a) NRF-1 that was bound to mef2a and δalas 
promoters, b) MEF2A that was bound to the glut4 promoter, in Dox-treated C2C12-Tet-On-NRF-1 
myotubes or caffeine treated C2C12 myotubes, and c) Acetylation levels of histones in the vicinity 
of NRF-1 binding domain on mef2a promoter and of histones in the neighbourhood of the MEF2A 
binding site on the glut4 promoter in C2C12 myotubes.  
                3.9.1. Primer design for ChIP assay: Primers were designed using Primer 3 software 
using the genome sequences posted in the NIH genome database (PUBMED). Primer pairs 
(forward and reverse), were designed to span the NRF-1 binding site on mef2a and δalas promoters 
and the MEF2 site on the glut4 promoter. These are refered to as positive (+ ve) primers in this 
thesis. Negative control primers (-ve), which span a sequence of DNA without NRF-1 or MEF2 
binding sequences were designed to be a least ~3 kb away from primers at corresponding NRF-1 or 
MEF2 binding sites. The following criteria were used for selection of primers: a) they had to have 
least potential to form inter- or intra primer dimmers and hairpins, b) the GC content was between 
50-66 % , c) the melting temperature was 55-70 
o
C,  d) they contained 18-24 bp of  nucleotides, and 
e) transcript size was between 250-340 bp.  
Table 3.3: Primers used in the ChIP assays. 
 
 
 
 
 
 
Designed Primer name Amplicon 
size 
Forward (F) and Reverse primer (R) 
GLUT4-MEF2A    (+VE) 268 bp F: 5‟- CAG GCA TGG TCT CCA CAT ACA C-3‟ 
R: 5‟ –GGT AAC  TCC AGC AGG ATG ACA-3‟ 
GLUT4-MEF2A  (-VE) 315 bp F: 5‟ – CCA ACA GCT CTC AGG CAT-3‟ 
R: 5‟ – CCA TTC CAC AGG CAA GCA G-3‟ 
MEF2A-NRF-1  (+VE) 315 bp F: 5‟ – CCT TCC TGT GCC GGG TGA TCT-3‟ 
R: 5‟ –CTA TTT TTA GGA GTC AGG CCC GG-3‟ 
MEF2A-NRF-1 (-VE) 250 bp F: 5‟ –AGT TGT GCC ACC TGT CCC A-3‟ 
R: 5‟ –CAA TGT CAG CTC ACA CTC A-3‟ 
ALAS-NRF-1 (+VE)  260 bp F: 5‟-TAG AAG GAG CAG AGG GAC GA-3‟ 
R: 5‟-TGT TCA CGA GCA GCC TAA GG-3‟ 
ALAS-NRF-1 (-VE) 339 bp F: 5‟-TCT CGT AGA CTC CAC GTG CAT-3‟ 
R: 5‟-AGT GCC CAG GAC AGG ATT AC-3‟ 
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3.9.2. Treatment of myotubes for ChIP assay: C2C12-Tet-On-NRF-1 cells were grown for 
10-13 days to form myotubes as described in section 3.3. To stimulate NRF-1 overexpression, 1 
μg/ml Dox was added to and kept in the medium for 6 h.  After the Dox treatment, cells were 
washed with 1 x PBS to remove Dox and incubated in fresh medium for additional 6-8 h. C2C12-
Tet-On-NRF-1 cells that were treated with vehicle (No Dox) served as controls. Differentiated wild 
type C2C12 myotubes were treated with 10 mM caffeine in the presence or absence of 25 μM 
KN93 and incubated for 2 h after which cells were washed and incubated in DMEM only for 
further 6 h.  
3.9.3. The ChIP assay protocol: To assess changes that occurred in the amount of NRF-1 
that bound to mef2a and alas promoters and MEF2A that bound to the glut4 promoter in response 
to Dox or caffeine, ChIP assays were used (146). After treatments, formaldehyde was added to the 
medium to a concentration of 1% (v/v) to crosslink protein to DNA and protein to protein. 
Crosslinking was allowed to proceed for 10 min and stopped by adding glycine to the medium to a 
concentration of 0.125 M. Cells were then washed twice with cold PBS containing 1 x complete 
protease inhibitors (Roche), scraped into an eppendorf tube on ice and centrifuged (1200 x g, 4 min, 
4 
o
C) on a bench top microfuge. After removal of the supernatant, the pellet was sonicated in 500 l 
nuclear lysis buffer (1 % SDS, 50 mM Tris-HCl, pH 8.0, 10 mM EDTA + 1 x complete protease 
inhibitors) on ice to shear chromatin using a Virsonic 60 sonicator (Virtis). With the sonicator set at 
33 % of maximal power, chromatin was sheared to the desired size of ~300-1000 bp by 8 cycles (60 
s rests between cycles) of 20 s pulses of sonication. The tube containing sonicated solution was 
centrifuged at 13000 rpm for 10 min and the supernatant (containing chromatin fragments) 
transferred to a new tube. Endogenous immunoglobin was pre-cleared by incubating with 30 l (60 
g) of 50 % salmon sperm DNA/protein A agarose slurry (Santa Cruz) for an hour at 4 
o
C (with 
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shaking) followed by centrifugation at 1000 x g for 1 min. The resultant supernatant containing 
chromatin was referred to as the „input‟ sample (IN). Chromatin from 100 μl of the input sample 
was diluted 1:10 in ChIP dilution buffer (0.1 % SDS, 1 % Triton X-100, 1.2 mM EDTA, 16.7 mM, 
Tris-HCl, pH 8.1, 167 mM NaCl and 1 x complete protease inhibitors). This was incubated with 5 
l MEF2A (Cell signalling) or NRF-1 (Abcam) antibodies, or with 5 l IgG (Cell signalling) on a 
rocking platform at 4 
o
C for 24-48 h. After the incubation, the immuno-complexes were 
precipitated with 60 l (120 g) of the 50 % salmon sperm DNA/protein A agarose bead slurry 
(Santa Cruz) for 2 h in a rocking platform at 4 
o
C. The beads were pelleted by centrifugation at 
5500 x g for 1 min at 4
  o
C and the pellet, washed sequentially with low salt buffer (0.1 % SDS, 1 % 
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl), high salt buffer (0.1 % 
SDS, 1 % Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 500 mM NaCl), Lithium chloride 
buffer (250 mM LiCl, 1 % NP-40, 1 % sodium deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 
8.0) and twice with TE buffer (10 mM  Tris-HCl pH 8.1, 1 mM EDTA). The washing steps were 
done by adding 1 ml of each buffer, shaking the tubes for 5 min on a rocking platform and 
centrifuging at 5500 x g at 4 
o
C except during the last wash (with TE buffer) which was carried out 
at room temperature. Elution was done with 150 l elution buffer (1 % SDS, 100 mM NaHCO3) for 
15 min at room temperature and repeated twice to make a 300 l final volume. The eluted 
immunoprecipitated sample (IP), and equal volume of IN sample were decross-linked by incubation 
in 0.3 M NaCl at 65 °C for 6 h. After digestion of proteins by proteinase K (10 μg/μl) for 1 h at 45 
o
C, DNA fragments were purified, using the phenol-chloroform extraction method, to yield IP and 
IN DNA samples respectively. Phenol-chloroform extraction was performed as follows:  One 
volume of Phenol was added the DNA sample, mixed for 5 min and centrifugation at 12000 x g for 
3 min. The aqueous phase was added to an equal volume of phenol:chloroform:isoamyl alcohol 
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(25:24:1), shaken for 5 min, and centrifuged at 12000 x g. The aqueous portion was mixed with an 
equal amount of chloroform:isoamyl alcohol (24:1) and centrifuged as before. The aqueous portion 
was transferred to a new tube containing 100 % ethanol, 0.3 M sodium acetate and glycogen and 
the DNA precipitated overnight at -20 
o
C. After centrifugation at 12000 x g for 15 min, the DNA 
pellet was washed in 70 % ethanol, air dried and then re-suspended in 20 μl dH2O. The DNA 
concentration was determined by measuring absorbance at 260 nm in a quartz cuvette using a 
spectrophotometer and DNA concentration was calculated by the dilution multiplying the 
absorbance obtained dilution factor and 50 g/ml.  
3.9.3.1. Assessment of mef2a promoter-bound NRF-1: To assess the amount of NRF-1 that 
was bound to  the mouse mef2a gene (AC120123), a 315 bp fragment corresponding to nucleotides 
-308 to +7 of the mouse mef2a gene containing the NRF-1 cis-element was PCR amplified from 
purified IN DNA and from the NRF-1 antibody co-immunoprecipitated DNA (IP). To control for 
antibody specificity, purified DNA from sample that had been treated with IgG was also PCR 
amplified. The PCR reaction consisted of  30 pmol of forward and reverse MEF2A-NRF-1 (+ve 
primers) (Table 3.3), 1 l of purified IP DNA, 1 l IN DNA or 1 l IgG immunoprecipitate, 0.2 
mM MgCl2, 0.5 U of SuperTherm Taq polymerase, 1 x SuperTherm buffer and 2 mM dNTPs). A 
250 bp fragment corresponding to nucleotides +2904 to +3154 (relative to the start of 
transcription), which does not contain the NRF-1 site, was used as a negative control. In this case 
the PCR reaction consisted of 30 pmol of forward and reverse MEF2A-NRF-1 (-ve primers) (Table 
3.3), 1 l of purified IP DNA, 1 l IN DNA or 1 l IgG immunoprecipitate, 1-3 mM MgCl2, 0.5 U 
of SuperTherm Taq polymerase, 1 x SuperTherm buffer, 0.2 mM  dNTPs). The PCR reaction was 
conducted as follows: 1 cycle of denaturing at 94 
o
C for 4 min followed by 35 cycles of 4 min of 
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denaturing at 94 
o
C, 30 s annealing at 63.5
 o
C, extension for 1 min at 72 
o
C and lastly, 1 cycle of 
final extension at 72 
o
C for 5 min. 
The PCR reactions were conducted under identical conditions as described above. Five to 
10 l of PCR products was separated by 2 % agarose gel electrophoresis to verify amplicon sizes.  
Figure 3.12, showing a typical gel, indicates that the primers used amplified fragments of 315 bp 
(+ve) and 250 bp (-ve) as expected. Lane 3 represents a PCR product after immunoprecipitation 
(IP) with IgG and amplification using +ve primers.  No signal is seen as expected. Lanes 2 and 5, 
which represents NRF-1- IP samples which underwent PCR using MEF2A-NRF-1 (+ve) and 
MEF2A-NRF-1 (-ve) primers (Table 3.3), showed a signal (lane 2) and no signal (lane 5) 
respectively as was expected. Lanes 1 & 4 represents PCR of Input samples using both MEF2A-
NRF-1 (+ve) and MEF2A-NRF-1 (-ve) primers which produced 315 bp and 250 bp products, 
respectively, as expected. 
 
Figure 3.12: The typical agarose gel from a ChIP assay performed in either C2C12-Tet-On-NRF-1 cells treated 
with Dox or C2C12 myotubes treated with caffeine. Lanes 1 & 4 shows PCR conducted on input samples (IN) with 
positive (315 bp) and negative primers (250 bp), respectively. Lanes 2 & 5 show a PCR conducted on IP (NRF-1 
immunoprecipitation) samples with both positive (315 bp) and negative primers (250 bp) respectively. Lane 3 shows 
PCR done with positive primers on IgG IP samples used as a control. These results demonstrate the high specificity of 
our assay. 
  
 3.9.3.2. Assessment of δalas promoter-bound NRF-1: For measurement of alas promoter-
bound NRF-1, a 260 bp fragment corresponding to nucleotides -236 to +24 of the mouse alas gene 
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containing NRF-1 binding site was amplified by PCR. In this case, the PCR reaction consisted of 
20 pmol of forward and reverse δALAS-NRF-1 (+ve primers) (Table 3.3), 1 l of purified IP DNA, 
1 l IN DNA or 1 l IgG immunoprecipitate, 3 mM MgCl2, 0.5 U of SuperTherm Taq polymerase 
(Medox Biotech, Chennai, India), 1 x SuperTherm buffer and 0.2 mM  dNTPs. The PCR reaction 
was conducted as follows: 1 cycle of 4 min denaturing at 94 
o
C followed by 35 cycles of 30 s 
denaturing at 94 
o
C, 30 s annealing at 63 
o
C, 1 min extension at 72 
o
C and lastly, 1 cycle of 5 min 
final extension at 72 
o
C. 
Like wise, a 339 bp fragment corresponding to nucleotides -8404 to -8065 (relative to the 
start of transcription), which does not contain the NRF-1 site, was used as a negative control. This 
site was amplified using δALAS-NRF-1 (-ve primers) (Table 3.3). In this case the PCR reaction was 
conducted similarly as for the δALAS-NRF-1 (+ve primers) described above. 
3.9.3.3. Measurement of glut4 promoter-bound MEF2A: A 268 bp fragment 
corresponding
 
to nucleotides –604 to –336 of the mouse glut4 promoter containing the MEF2A 
binding site was amplified by PCR using 20 pmol of forward and reverse GLUT4-MEF2A (+ve 
primers) (Table 3.3), 1 l of purified IP DNA, 1 l IN DNA or 1 l IgG immunoprecipitate, 2.5 
mM.MgCl2, 0.5 U of SuperTherm Taq polymerase, 1 x SuperTherm buffer, 0.2 mM dNTPs. The 
PCR reaction was conducted as follows: 1 cycle of denaturing at 94 
o
C for 4 min followed by 35 
cycles of 30s denaturing at 94 
o
C, 30 s annealing at 64 
o
C, 1 min extension at 72 
o
C and lastly, 1 
cycle of 5 min final extension at 72 
o
C. 
  A 315 bp fragment corresponding to nucleotides +2,868
 
to +3,183 (relative to the start of 
transcription), which does
 
not contain the MEF2A site, was used as negative control. This
 
site was 
amplified using similar conditions used for the GLUT4-MEF2A (+ve
 
primers) described above. The 
amplified DNA fragments were separated by electrophoresis on 2 % agarose gels as described 
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under section 3.9.3.1. Figure 3.13, shows a typical gel. The figure verifies that the positive primers 
amplified 268 bp fragments (lanes 1 and 2) and the -ve primers amplified 315 bp fragments (lane 
4), as expected. Lane 3 represents immunoprecipitation with IgG which did not produce any signal 
as expected. Lanes 1 & 4 represents PCR of Input samples using both GLUT4-MEF2A (+ve) and 
GLUT4-MEF2A (-ve) primers which produced 268 bp and 315 bp products, respectively, as 
expected. 
 
 
 
Figure 3.13: The typical agarose gel showing a ChIP assay performed in either C2C12-Tet-On-NRF-1 treated 
with Dox or C2C12 myotubes treated with caffeine. Lanes 1 & 4 show PCR conducted on input samples (IN) with 
positive (268 bp) and negative (315 bp) primers respectively. Lanes 2 & 5 show a PCR conducted on IP (MEF2A 
immunoprecipitation) samples with positive (268 bp) and negative (315 bp) primers respectively. Lane 3 shows PCR 
done with positive primers on IgG IP samples used as a control. 
 
 3.9.3.4. Assessment of acetylation of histones at NRF-1 and MEF2A binding domains: 
For assessment of histone acetylation, ChIP assay was performed as described in sections 3.9.3.1-3. 
We assessed the levels of acetylation of histone H3 in the vicinity of the NRF-1 binding site on the 
mouse mef2a gene, and MEF2A binding domain on the glut4 gene. Immunoprecipitation was done 
using antibodies against histone H3 and acetyl histone H3 (Cell signalling). The amount of co-
immunoprecipitated mef2a and glut4 gene sections were assessed by PCR using appropriate 
primers (i.e. the same +ve and –ve primers shown in table 3.3).  
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Table 3.4: Antibodies and antibody dilution for ChIP assays. 
Antibodies used for ChIP assay antibody dilution 
Acetyl histone H3 (Lys9/Lys14); Histone H3; 
Mouse IgG (Cell Signalling). 
 (5 μl of antibody in 1 ml ChIP assay 
sample) 
MEF2A (Cell signalling) and NRF-1 
(Abcam)  
In ChIP assay, a 5 μl of each antibody 
was added into 1 ml ChIP assay sample. 
3.10. RNA analysis 
         After analysing the binding levels of NRF-1 and MEF2A on mef2a and glut4 promoters  
respectively after CaMK II activation, we investigated how the levels of MEF2A and GLUT4 
mRNA under the same conditions were. C2C12 were grown as before until they had formed 
myotubes. They were treated with caffeine or caffeine with KN93 for 2 h, washed and incubated in 
fresh DMEM medium for 6 h, and harvested.  
       Primers for quantitative real time PCR, and semi quantitative RT-PCR were designed to span 
exon-exon boundary segments to avoid amplifying genomic DNA. Exons were mapped using 
SPIDEY program (www.ncbi.nlm.nih.gov/spidey). The primers were designed using the Roche 
light cycler (LC) probe design and Primer 3 software from sequences posted from gene bank (NIH 
genome database, PUBMED). For oligonucleotides to qualify as primers, they had to have: a) low 
potential to form inter-or intra primer dimmers and hairpins, b) a GC content of 50-60 %, and c) 
16–21 bp. 
 3.10.1. RNA gels and preparation: Gel tanks, trays, and combs were thoroughly washed 
with detergent and thereafter rinsed well with water. The agarose powder was dissolved in 10 % of 
10 x MOPS (0.2 M MOPS pH 5.5, 0.05 M sodium acetate, 0.01 M) in DEPC water. The powder 
was heated and dissolved in a microwave and then cooled to 60 
o
C. Formaldehyde (4.9 % of 12.3 
M) and 0.5 μg/ml ethidium bromide were added and mixed and poured onto trays and allowed to 
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set. The gel was then placed in a tank wherein 1 x MOPS running buffer was added. RNA (2-5 μg) 
samples were mixed with RNA formaldehyde loading buffer (0.8 % of 0.5 M EDTA, 7.2 % 
formaldehyde, 20 % glycerol, 30 % formamide, 40 % 10 x MOPS, 0.8 % Bromophenol blue dye) 
vortexed, centrifuged, heated at 55 
o
C for 15 min, and loaded onto wells and separated by 
electrophoresis. Electrophoresis was performed at 50 V until the RNA bands were well separated 
and a photograph of the bands taken. The 28S rRNA and 18S rRNA bands were inspected visually 
to assess the integrity of the RNA. When the integrity of the RNA was acceptable, the 
concentration of RNA was determined spectrophotometrically at 260 nm and the RNA used in the 
experiments. 
 3.10.2. Measurement of MEF2A and GLUT4 mRNA: Well differentiated myotubes were 
serum-starved overnight and incubated with 10 mM caffeine in the presence or absence of 25 μM 
KN93. Myotubes were harvested 6 h post treatment and RNA was isolated using 1 ml of Trizol 
reagent according to the manufacturer‟s instructions (Ambion). Briefly, the medium was sucked 
from the plates after treatments and 1 ml of Trizol reagent added directly to the cells and the cells 
scraped loose from the plates. Cells were passes through the thin bore of a pipette several times to 
lyse the cells. The lysate were transferred to an RNase-free eppendorf tube and incubated at room 
temperature for 5 min to allow nucleoprotein complexes to dissociate completely. Thereafter, 200 
μl of chloroform was added. The tubes were tightly capped and vigorously shaken and then 
incubated further for 10 min at room temperature. The lysate were centrifuged at 12000 x g for 10 
min at 4 
oC and thereafter the aqueous phase was transferred to a fresh clean tube. Fifty μl of 
isopropanol was added and the mixture vortexed and incubated for 10 min at room temperature and 
finally centrifuged at 12000 x g for 8 min at 4 
o
C. The supernatant was removed without disturbing 
the pellet containing RNA. One ml of 75 % ethanol was added to wash the pellet followed by 
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centrifugation at 7500 x g for 5 min at 4 
o
C. Ethanol was removed and the pellet was air-dried and 
dissolved in DEPC-treated water and stored at -85 
o
C. The RNA quantity was assayed by 
measuring the absorbance at 260 nm and the integrity of the RNA was checked by running samples 
on a 1 % formaldehyde agarose gel as described above. Genomic DNA was eliminated from the 
samples by digestion with DNAse-1 for 90 min at 37 
o
C. DNAse-1 was subsequently deactivated 
by incubation at 75 
oC for 5 min. cDNA was synthesized from 1 μg of total RNA using 200U of M-
MLV reverse transcriptase (Promega) for 1 h in a reaction mixture containing 2 mM dNTPs, 2.5 
mM MgCl2, 20 U RNAsin and 1 x RT buffer. Real time PCR was performed in triplicate on the 
cDNA in a Light Cycler PCR machine (Roche) using SYBR Green PCR reagents from Roche and 
primers which amplify a 187 bp region in the mouse mef2a gene (Fwd 5‟-GTG TAC TCA GCA 
ATG CCG AC-3′; Rev 5‟-AAC CCT GAG ATA ACT GCC CTC-3‟). For GLUT4: primers that 
amplify a 270 bp
 
region in the mouse glut4 gene (forward 5'-GCAGCGAGTGACTGGAACA-3';
 
reverse 5'-CCA GCC ACG TTG CAT TGT AG-3'). Relative mRNA concentrations were 
calculated using the PCR threshold cycle according to the method described by (140). Mean values 
were corrected to mouse GAPDH (Fwd 5'–GCA CAG TCA AGG CCG AGA AT-3'; Rev 5'-GCC 
TTC TCC ATG GTG GTG AA-3') and Ribosome S12 (Fwd 5-GGA AGG CAT AGC TGC TGG 
AGG TGT-3‟; Rev 5‟-CGA TGA CAT CCT TGG CCT GAG-3‟) genes (internal controls) and 
expressed relative to a control in each experiment. 
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 Table 3.5: Characteristics of the primers used to amplify the mouse cDNA and mRNA.  
 
Mouse GAPDH- Glyceraldehyde 3-phosphate dehydrogenase; RS12-Ribosomal protein S12; GLUT4-Glucose 
transporter 4; MEF2-myocyte enhancing factor 2; mRNA-messenger ribonucleic acid; cDNA- complementary 
deoxyribonucleic acid. F- Forward primer; R- Reverse primer, bp= base pair. 
3.11. Statistics 
         Data were presented as means ± SD. Statistical differences between treatments were 
determined using a one-way ANOVA. Significance was accepted at p < 0.05. When the ANOVA 
test showed a significant difference, post hoc analysis was performed using LSD or Fisher‟s test. 
STATISTICA 9 software was used for these analyses. 
 
 
 
 
 
 
 
 
 
 
 
Name  Primers Product size mRNA cDNA 
GLUT4 
 
F: 5‟-GCA GCG AGT  GAC TGG AAC A-3‟ 
R: 5‟-CCA GCC ACG TTG CAT TGT AG -3‟ 
270 bp   X  
MEF2A 
 
F: 5‟- GTG TAC TCA GCA ATG CCG AC -3′  
R: 5′- AAC CCT GAG ATA ACT GCC CTC -3′  
187 bp    X  
GAPDH 
 
F-5‟-GCA CAG TCA AGG CCG AGA AT-3‟ 
R-5-GCC TTC TCC ATG GTG GTG AA-3‟ 
100 bp    X  
RS12 F-5‟-GGA AGG CAT AGC TGC TGG AGG TGT-3‟ 
R- 5‟-CGA TGA CAT CCT  TGG CCT GAG -3‟ 
380 bp    X    
NRF-1 
 
F: 5‟-GTT GGA TCC CTC TCA CCC ATT G - 3‟ 
R: 5‟ - CCA AGT CGA GAC TTA ATT CC-3‟ 
1740 bp     X 
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CHAPTER 4 
Study One: 
Stimulation of GLUT4 expression by NRF-1 is mediated by MEF2A 
4.1. Introduction 
 As mentioned in Section 1.1, overexpression of NRF-1 in transgenic mice induce significant 
increases in MEF2A and GLUT4 proteins, and enhanced glucose transport capacity in muscle (10) 
(Baar et al., 2003). The aim of our first study was to investigate the mechanisms involved in the 
increase in GLUT4 protein in response to NRF-1 overexpression. We hypothesized that NRF-1 
overexpression stimulates MEF2A expression, which in turn induces GLUT4 up-regulation. Our 
hypothesis was derived from the following observations: a) NRF-1 cis-element is absent in the glut4 
gene but present in the mef2a gene (10; 185) b) overexpression of NRF-1 increases MEF2A protein 
content (10) c) glut4 gene is regulated by MEF2 transcription factors (223), and d) overexpression of 
MEF2A in myotubes increases GLUT4 expression (197). 
 The study was performed using the NRF-1 overexpressing C2C12-Tet-On-NRF-1 cell line 
which was developed as described in Section 3.4. The first set of experiments was conducted to 
verify that the transgenic myotubes that we engineered effectively overexpressed NRF-1 in the 
presence of Dox. Following this verification, we measured the contents of GLUT4 and MEF2A 
proteins to ascertain that they were increased as expected (10). Having determined that our cell 
culture system effectively increased GLUT4 and MEF2A proteins in response to NRF-1 
overexpression, we performed experiments to determine: a) if the increase in MEF2A was necessary 
for GLUT4 up-regulation using MEF2A-siRNA and b) the amount of NRF-1 that was bound to the 
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mef2a promoter and MEF2A bound to the glut4 promoter. A description of the experimental methods 
and our findings are presented and discussed below. 
4.2. Methodology  
4.2.1. Treatment of myotubes: The C2C12-Tet-On-NRF-1 clones that had high NRF-1 
protein expression in response to Dox and low background (without Dox) were verified by western 
blot as described in section 3.7.3. Myoblasts were incubated in medium containing 2 % horse serum 
for a period of up to 13 days to form myotubes. To overexpress NRF-1 protein in these myotubes, 
they were incubated in medium containing 1 μg/ml Dox for 6 or 72 h. Myotubes that were incubated 
with an equal volume of vehicle, and wild type C2C12 myotubes, served as controls. After 72 h 
treatments (Dox or vehicle), cells were washed and incubated in Dox-free medium for 0, 6 or 18 h,  
homogenized and the total protein content was measured using the Bradford assay. The protocols 
used for protein extraction and assay were presented in detail in sections 3.7.1-3. For binding assays, 
C2C12-Tet-On-NRF-1 myotubes we incubated with Dox or vehicle for 6 h, washed with PBS, 
incubated in medium for 6-8 h and fixed in 1 % formaldehyde for 10 min.   
  4.2.2. Assessment of NRF-1 overexpression: One hundred μg of protein homogenate from 
the crude extracts was loaded onto a 7.5 % SDS-polyacrylamide gel and the component proteins 
separated by electrophoresis at 100 mV for 1-2 h. Subsequently, proteins from the gel were 
transferred onto a PDVF membrane in a BioRad transfer unit at 150 mA for 3 h at 4 
o
C and the 
membrane was blocked in 5 % fat-free milk or BSA overnight. The contents of NRF-1 and -tubulin 
(used as a control) were then measured by western blot as described before (Section 3.7.3). Briefly, 
the membrane was incubated overnight at 4 C (with rotation) in PBS-T containing a 1:2000 dilution 
of anti-NRF-1 antibody (Abcam) in PBST and 1 % fat-free milk or BSA, washed in PBST and again 
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incubated  in a solution containing a 1:10000 dilution of anti-rabbit secondary antibody (Dako) in 
PBST for 2 h at room temperature (see table 3.2). The signal was detected using enhanced 
chemiluminescence (ECL, Amersham) and the relative abundance of NRF-1 protein from the blot 
quantified using densitometry, as described in section 3.7.3. The NRF-1 signal was normalized to -
tubulin signal for comparison. 
4.2.3. Measurement of MEF2A, GLUT4 and δALAS contents: After establishing that 
C2C12-Tet-On-NRF-1 myotubes overexpress NRF-1 in response to Dox treatment, we then 
measured the contents of MEF2A, GLUT4 and δALAS proteins in Dox-treated myotubes and 
compared them to the contents in vehicle-treated and wild-type C2C12 myotubes using western blot. 
The western blot protocol used was described in section 4.2.2, except for the following modifications:  
For assessment of GLUT4, MEF2A and δALAS contents, 20 g of total protein was used in the SDS-
PAGE. Anti-GLUT4 (diluted 1:2000, Cell signalling), anti-MEF2A (1:2000 dilution, Cell signalling), 
and anti-δALAS (1:500, Santa Cruz) specific antibodies in TBST containing 5 % BSA (Sigma) were 
used. After washing the membrane with TBST, it was incubated in a solution containing anti-rabbit 
(Dako, Carpinteria, CA) or anti-goat HRP-linked secondary antibody (1:10000 dilution, Dako, 
Capinteria, CA) for 2 h at room temperature. After incubation in ECL (Amersham) reagent for 3-5 
min, membranes were autographed using Kodak film and the magnitude of the signals quantified 
using densitometry as described in section 3.7.3.           
  4.2.4. Silencing of MEF2A expression: To test whether MEF2A was responsible for the 
increase in GLUT4 expression in Dox-treated C2C12-Tet-On-NRF-1 myotubes, we transfected the 
myotubes (in 6 well plates) with 60 pmol MEF2A-siRNA (sc-35895; Santa Cruz) or control-siRNA 
(sc-37007; Santa Cruz) for 60 h using Lipofectamine as described previously in section 3.5.2. The 
concentration of MEF2A-siRNA and Control-siRNA (Santa Cruz) that we used was based on the 
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results of pilot experiments described in section 3.5.3. Myotubes were treated with 1 μg/ml Dox 12 h 
prior the transfection and cultured for further 60 h in the presence MEF2A-siRNA or Control-siRNA 
(Santa Cruz). C2C12-Tet-On-NRF-1 myotubes that were not incubated with Dox or transfected with 
either MEF2A-siRNA or control-siRNA (Santa Cruz) served as further controls. 
4.2.5. ChIP assays: The relative amounts of NRF-1 that bound to mef2a and δalas promoters 
in Dox- and vehicle-treated C2C12-Tet-On-NRF-1 myotubes were assessed using ChIP assay. The 
assay protocol is described in detail in section 3.9.3. Briefly, the formaldehyde-fixed myotubes 
(described in section 4.2.1) were sonicated to fragment the chromatin to 300-1000 bp and the 
chromatin fragments immunoprecipitated using anti-NRF-1 (Abcam) or anti-MEF2A (Cell 
Signalling) antibodies. IgG (Cell signalling), which does not recognize NRF-1 and MEF2A proteins, 
was used as a control antibody. Co-immunoprecipitated DNA was PCR amplified using primers that 
recognize the NRF-1 sites on the mef2a and δalas genes or MEF2 site on the glut4 gene. Control 
primers that targeted regions which do not contain the NRF-1 binding site on the mef2a and δalas 
genes, or MEF2 site on the glut4 gene were also used as controls. Criteria for primer selection were 
described in detail in section 3.9.1 and primer sequences are shown in table 3.3. PCR products were 
electrophoresed on 2 % agarose gel and the signals quantified by densitometry. Signal from the 
immunoprecipitated chromatin (IP) was normalised to its corresponding input signal (IN) i.e. signal 
from chromatin that did not undergo immunoprecipitation. 
 4.3. Results & Discussion 
 
4.3.1. Verification of NRF-1 overexpression in C2C12-Tet-On-NRF-1 myotubes: We began 
by verifying that C2C12-Tet-On-NRF-1 myotubes effectively overexpressed NRF-1 protein in the 
presence of Dox. Figures 4.1A and 4.1B indicate that, unlike wild-type C2C12 myotubes which were 
non-responsive to Dox treatment, C2C12-Tet-On-NRF-1 myotubes expressed ~ 6-fold higher NRF-1 
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when treated with 1 μg/ml Dox for 72 h relative to vehicle-treated controls. This result confirms that 
the double-stable C2C12-Tet-On-NRF-1 myotubes that we used caused high induction of NRF-1 
with Dox treatment with low background (without Dox). Clones that were not responsive to Dox, and 
those with high NRF-1 levels in the absence of Dox (high background), were not used in the 
experiments. High induction of NRF-1 in the absence of Dox may occur if the two transfected 
plasmids become co-integrated into the chromosome (15; 74) whereas non-responsiveness to Dox 
may occur in clones that failed to incorporate the pTRE2Hyg-NRF-1 (the second plasmid) in their 
genome after transfection (15; 236). Because Dox treatment caused overexpression of NRF-1 in 
transgenic but not wild-type C2C12 myotubes, it may be concluded that Dox increases NRF-1 
expression via the transfected plasmids and not via endogenous nrf-1 gene. Unlike NRF-1, the 
content of α-tubulin was not altered by Dox treatment in both C2C12-Tet-On-NRF-1 and C2C12 
myotubes; indicating that Dox treatment does not increase protein expression globally.                
 
Figure 4.1: NRF-1 expression in C2C12-Tet-On-NRF-1 and wild-type C2C12 myotubes in response to Dox 
treatment. Western blot for NRF-1 protein from double stable C2C12-Tet-On-NRF-1 (A) or wild-type C2C12 (B) 
myotubes harvested 18 h after 72 h treatment with 1 μg/ml Dox or vehicle. Representative blots for NRF-1 (~68 kDa) and 
α-tubulin (~51 kDa) are shown below the graphs. n = 4, * P = 0.004 vs vehicle. Data presented as means ± SD.  
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4.3.2. Overexpression of NRF-1 increases the expression of MEF2A, GLUT4 and δALAS 
proteins: The contents of MEF2A, GLUT4, δALAS and -tubulin in C2C12-Tet-On-NRF-1 
myotubes that were treated with 1 μg/ml Dox or equal volume of vehicle for 72 h were measured by 
western blot 18 h post treatment. Wild-type C2C12 myotubes that were similarly treated with Dox or 
vehicle served as further controls. The contents of MEF2A, GLUT4 and δALAS but not -tubulin 
were ~4-fold higher in Dox-treated C2C12-Tet-On myotubes compared to vehicle-treated controls 
(Fig 4.2A). Similar increases in these proteins have previously been reported in NRF-1 transgenic 
mice (10). The increase in δALAS protein, which we used here as an index for mitochondrial 
biogenesis (135), validates our research model since overexpression of NRF-1 in an animal model 
(10) increased the expression of δALAS as it does in our cell culture system. Because no significant 
increase in MEF2A, GLUT4 or δALAS was observed in wild-type C2C12 myotubes in response to 
Dox treatment (Fig 4.2B), it is logical to conclude that the increases in these proteins in C2C12-Tet-
On-NRF-1 myotubes resulted from NRF-1 overexpression. It is not surprising that NRF-1 
overexpression would increase the expression of MEF2A and δALAS but not -tubulin because 
functional NRF-1 cis-elements are present on mef2a and δalas promoters (135; 185) but absent on the 
-tubulin promoter (NCBI database DNA sequence search).     
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Figure 4.2: MEF2A, GLUT4 & δALAS expression in C2C12-Tet-On-NRF-1 and wild type C2C12 myotubes in 
response to Dox treatment. Western blot was performed to assay MEF2A, GLUT4 & δALAS protein levels from double 
stable C2C12-Tet-On-NRF-1 (A)  or wild-type C2C12 (B) myotubes when incubated with 1 μg/ml Dox or vehicle for 72 
h. Representative blots for MEF2A (~54 kDa) * P = 0.007 vs vehicle, GLUT4 (~45 kDa) P =0.002 vs vehicle & δALAS 
(~67 kDa) * P = 0.004 vs vehicle and α-tubulin (~51 kDa) are shown below the graphs. n = 4, * P < 0.05. Data presented 
as means ± SD. 
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4.3.3. Timeline of the increases in NRF-1, MEF2A and GLUT4: Although GLUT4 up-
regulation in response to NRF-1 overexpression has been observed before (10), the mechanism 
responsible remains unclear. In this experiment, we hypothesised that it occurs because of the 
increase in MEF2A content since numerous studies (94; 162; 223) have shown that MEF2A activates 
GLUT4 expression when it binds to its domain on the glut4 promoter. For our hypothesis to be true, 
the increase in NRF-1 ought to preceed the increase MEF2A which in turn should preceed the 
increase in GLUT4. To check if the increases in NRF-1, MEF2A and GLUT4 followed this predicted 
timeline, we cultured C2C12-Tet-On-NRF-1 myotubes for 6 h in Dox and measured the contents of 
NRF-1, MEF2A and GLUT4 at 0, 6, and 18 h post treatment. Figure 4.3 B shows that, in Dox-treated 
myotubes, NRF-1 tended to be higher at 0 h (p=0.052), was  significantly higher at 6 h and remained 
elevated for up to 18 h, compared to vehicle-treated controls. MEF2A was increased at 6 h and 18 h 
(Fig 4.3 B) but not at 0 h post Dox, whereas GLUT4 was only significantly increased after 18 h (Fig 
4.3 B). The timeline of the increases in NRF-1, MEF2A and GLUT4 is consistant with our 
hypothesis, and provides preliminary evidence that the increase in GLUT4 expression in NRF-1 
overexpressing cells occurs via cascade of events involving NRF-1→MEF2A→GLUT4 expression. 
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Figure 4.3: Contents of NRF-1, MEF2A and GLUT4 proteins in C2C12-Tet-On-NRF-1 myotubes after 6 h Dox 
treatment. A: Western blots were performed to assay NRF-1 (68 kDa), MEF2A (54 kDa) and GLUT4 (45 kDa) protein 
levels from double stable C2C12-Tet-On-NRF-1 myotubes at  0 h, 6 h and 18 h after 6 h treatment with with 1 μg/ml Dox 
or vehicle. B: Graphic representation of NRF-1, MEF2A, and GLUT4 proteins at various time points. n = 4, * P < 0.05; # 
P = 0.052. Data presented as means ± SD. 
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4.3.4. MEF2A is necessary for the increase in GLUT4 protein in response to NRF-1 
overexpression. To test if the increase in MEF2A content was responsible for GLUT4 up-regulation 
in Dox-treated C2C12-Tet-NRF-1 myotubes, we transfected the myotubes with either  the MEF2A-
siRNA or control-siRNA, incubated the transfected myotubes in medium containing 1 μg/ml Dox for 
60 h, and performed western blots for MEF2A, GLUT4 and -tubulin. Figure 4.4A shows that 
MEF2A expression was silenced by MEF2A-siRNA (treatments B vs. C) but not by control-siRNA 
(treatments B vs. D) in Dox-treated cells; indicating that transfection of MEF2A-siRNA specifically, 
and not transfection of siRNA per se, was the cause of MEF2A downregulation. Alpha-tubulin was 
not affected by control-siRNA or MEF2A-siRNA; indicating that MEF2A siRNA selectively silenced 
MEF2A expression.  
        Changes in GLUT4 expression in C2C12-Tet-On-NRF-1 myotubes followed the same pattern as 
changes in MEF2A expression: i.e. Dox-treatment increased GLUT4 significantly and the increase 
was blocked by MEF2A-siRNA and not by control-siRNA (Fig 4.4B). This data provides the first 
strong evidence that the increase in GLUT4 expression that occurs in response to NRF-1 
overexpression requires a parallel increase in MEF2A expression. This result is not surprising 
because MEF2A is one of the major regulators of GLUT4 expression (162; 223).   
There are four isoforms of MEF2 transcription factors, namely MEF2A, MEF2B, MEF2C and 
MEF2D (18; 145) which dimerize in order to bind to a well conserved consensus sequence on genes. 
It has been reported that the MEF2A/D heterodimer and the MEF2A/A homodimer regulate the glut4 
gene (124; 157; 162). It is therefore not surprising that when the MEF2A isoforms is silenced, as we 
did in our experiments, GLUT4 expression would be compromised because neither the MEF2A/D 
nor the MEF2A/A would be available. In conclusion, the results of our experiment show that MEF2A 
is necessary for the increase in GLUT4 protein in response to NRF-1 overexpression.  
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Figure 4.4:  Silencing of MEF2A expression blocks the increase in GLUT4 content in NRF-1 overexpressing cells. 
C2C12-Tet-On myotubes that were transfected with MEF2A-siRNA or control siRNA were cultured in medium 
containing Dox (+) or vehicle (-) for 60 h. A: MEF2A protein (54 kDa) is increased by Dox treatment but significantly 
decreased by MEF2A-siRNA. B: GLUT4 protein (45 kDa) is also increased by Dox treatment and decreased by MEF2A-
siRNA. Control siRNA did not decrease MEF2A expression (as expected) and had no effect on GLUT4 expression. 
Representative western blot for MEF2A (54 kDa) *P = 0.002 vs MEF2-siRNA & * P = 0.005 vs control siRNA, GLUT4 
(45 kDa) *P = 0.009 vs MEF2-siRNA & * P = 0.001 vs control siRNA and α-tubulin (51 kDa) are shown below the 
graphs. n = 4, * P < 0.05. Data is presented as means ± SD. 
 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
  
72 
 
4.3.5. Dox increases the binding of NRF-1 and MEF2A to mef2a and glut4 promoters, 
respectively. To explain the increases in MEF2A and GLUT4 expression in Dox-treated C2C12-Tet-
NRF-1 myotubes, we measured the contents of NRF-1 and MEF2A that were bound to mef2a and 
and glut4 promoters, respectively. Myotubes were treated for 6 h with 1 μg/ml Dox and ChIP assays 
performed 6 h or 8 h later. Specificity of the the ChIP assay was verified as previously described in 
Chapter 3, Section 3.9.3.1: i.e.  a) there was no evidence of NRF-1 binding at the mef2a coding 
region in position +2904 - +3154 which has no NRF-1 binding element (Figure 3.12), and  b) only 
the anti-NRF-1, but not IgG, was able to co-immunoprecipitate the MEF2A binding domain (Fig 3.12 
lanes 2 and 3, respectively). Validity of the assay was verified when we showed that there was nearly 
~2.8-fold more δalas-bound NRF-1 in Dox-treated myotubes compared to vehicle-treated controls 
(Figure 4.5A) because the result is consistent with previous finding by Li et al. (135) who showed, by 
EMSA, that NRF-1 overexpression in mice increased NRF-1 binding to the δalas gene. Figure 4.5A 
indicates that there was ~2.8-fold increase in mef2a-bound NRF-1 due to Dox compared to controls. 
This result is not surprising since NRF-1 content was also increased at this time point (6 h). It is well 
documented that binding of a transcription factor to DNA is influenced by its abundance (75; 112). 
Figure 4.5C shows that glut4-bound MEF2A was also increased ~2.7-fold at the 8 h time point. 
Again this result is not surprising since MEF2A was already elevated at this time point (Figure 4.3B). 
GLUT4 content was increased at 18 h but not at 6 h (Figure 4.3 C); indicating that MEF2A binding to 
the gene preceed transcription and translation of the glut4 gene as expected. We suspect that the 
dramatic reduction in GLUT4 expression that occurred when MEF2A expression was silenced (Fig 
4.4A & B) was a result of a reduction in the level of glut4-bound MEF2A. Collectively these results 
indicate that the increases in GLUT4 that occur when NRF-1 is overexpressed are mediated by 
increased binding of NRF-1 to the mef2a gene and MEF2A to the glut4 gene resulting from increased 
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abundance of NRF-1 and MEF2A in cells. Thes results are consistent with the general observation 
that an increase in the total content of a transcription factor in cells often reflects a rise in nuclear 
content as well, and is often accompanied by enhanced binding to appropriate DNApromoter 
sequences (94; 162; 223) to promote transcriptional activity. For example, a study by Holmes et al. 
(94) showed that when the total content of MEF2A protein was increased in rat muscle as a result of 
AICAR injection, a significant increase in nuclear MEF2A content also occurred and this ultimately 
resulted in ~2-fold increase in MEF2A binding to the glut4 promoter.  
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Figure 4.5: Overexpression of NRF-1 increases NRF-1 binding to the mef2a and δalas promoters. ChIP assays were 
used to assess mef2a-bound NRF-1*P = 0.01 vs vehicle (A), δalas-bound NRF-1 * P = 0.009 vs control (B) and  glut4-
bound MEF2A * P = 0.02 vs vehicle (C)  in C2C12-Tet-ON-NRF-1 myotubes that were incubated in medium containing 
1 μg/ml Dox or vehicle for 6 h, using appropriate antobodies. Co-immunoprecipitated promoter sections and DNA from 
an equal volume of input (non-immunoprecipitated) sample were PCR amplified using appropriate primers (section 3.9.3) 
and electrophoresed using 2% agarose gel. The graphs show the amplified co-immunoprecipitated promoter sections (IP) 
normalized to corresponding input (IN) signals. Representative PCR gels are shown below the graphs.  n = 4, * P < 0.05. 
Data presented as means ± SD.  
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4.4. Summary and concluding remarks 
Results from this study provide preliminary support for the hypothesis that overexpression of 
NRF-1 increases GLUT4 content through a cascade of events involving NRF-1  mef2a  MEF2A 
 glut4  GLUT4 in C2C12-Tet-On-NRF-1 myotubes. Suport for the cascade was provided by: a) 
the temporal relationships between the expression of NRF-1, MEF2A and GLUT4; b) abolishion of 
GLUT4 expression in NRF-1 overexpressing C2C12 myotubes when MEF2A was silenced,  and c) 
increases in mef2a-bound NRF-1 and glut4-bound MEF2A with NRF-1 overexpression. However, 
more confirmatory pieces of evidence for the hypothesis are still needed: Firstly, the timelines of 
MEF2A and GLUT4 mRNA levels should be determined to indicate whether or not the observed 
increases in binding cause increased transcriptional activity. Secondly, mef2a-bound NRF-1 and 
glut4-bound MEF2A should be assessed at more time points after treatment, especially between 0-6 h 
after treatment, to indicate whether on not these events occur sequencially as predicted by the 
hypothesis. We were unable to perform these experiments because of financial constraints.   
As mentioned in the text, we used an anti-MEF2A antibody which was raised against amino 
acids 1-300 of MEF2A (Santa Cruz Biotechnology) in most of our ChIP assays for glut4-bound 
MEF2A. Although this antibody reacts strongly with MEF2A, it also crossreacts to a lesser extent 
with the MEF2D and MEF2C isoforms, which are also expressed in skeletal muscle (162). The 
crossreactivity of this antibody to these MEF2 isoforms could have confounded some of our ChIP 
assay results. However, results using an anti-MEF2A antibody from Cell signalling (Cat no: 9736), 
which is reported not to crossreact with MEF2D or MEF2C were not different from those obtained 
using the Santa Cruz antibody; indicating that our ChIP assay results are still valid. 
In conclusion, not withstanding the preliminary nature of some of our data, our results 
confirm that NRF-1 regulates GLUT4 expression and suggests that interventions that increase its 
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expression or its interaction with the mef2a gene could be useful in the treatment and management of 
type II diabetes. 
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CHAPTER 5 
Study two: 
Increased binding of NRF-1 to the mef2a promoter requires CaMK II activation in C2C12 
myocytes 
 
5.1. Introduction 
 In the previous chapter we showed that overexpression of NRF-1 in cultured muscle cells 
(C2C12 myotubes) enhanced the binding of NRF-1 to the mef2a gene and increased MEF2A protein 
content. Similar increases in MEF2A content have previously been reported in L6 myotubes that 
were treated with caffeine (173). In those studies, caffeine was used to activate CaMK II since it 
increases cytosolic calcium levels (172; 173). Inclusion of KN93 (an inhibitor of CaMK II) in the 
medium together with caffeine blocked the increase in MEF2A. This observation led the authors to 
conclude that the caffeine-induced increase in MEF2A was dependent on CaMK II activation.  
Although the mechanism by which CaMK II regulates MEF2A expression has not been well defined, 
there is some evidence to support the notion that it affects the binding of transcription factors, such as 
NRF-1, to their elements on genes. For example, Ojuka et al., (172; 173) showed that treatment of 
myotubes with caffeine increased NRF-1 binding to a δalas promoter sequence in a CaMK II -
dependent manner. Marechal et al. (152) also demonstrated that DNA binding activity of hGT-1 to 
BoxII on rbcS (Ribulose-1, 5-bisphosphate carboxylase) promoter is increased ~10-20 -fold in the 
presence of purified activated CaMK II when measured by electrophoretic DNA mobility shift assay. 
Addition of KN93 blocked the increase in hGT-1 binding to Box II region. Similarly, CaMK II 
activation also increased AP-1 binding to c-fos promoter (240). In light of these observations, and 
because NRF-1 regulates MEF2A expression (10), we hypothesized that CaMK II activation by 
caffeine might increase MEF2A expression via increased NRF-1 binding to the mef2a gene.  
Un
ive
rsi
y O
f C
ap
e T
wn
 
  
78 
 
Binding of transcription factors to DNA depends on the compactness of chromatin at the 
binding site, which depends on the interplay between the activities of HDACs and HATs (76; 143). 
HDACs remove acetyl moieties from lysine residues on histone tails in chromatin and cause 
chromatin to become more compact (3; 217), whereas HATs acetylate the same residues and relaxes 
chromatin. A number of studies have shown that activation of CaMK II in fibroblasts (10T1/2) and 
Cos cells (monkey kidney cells) cause phosphorylation and nuclear export of HDAC4/5 (136; 143; 
158). Reduced nuclear content of HDACs increases nuclear HAT activity which remodels chromatin 
to favour increased accessibility of transcription factors to their respective binding domains on DNA. 
Whether CaMK II activation by caffeine promotes NRF-1 binding to the mef2a gene via a similar 
mechanism is currently not known. The purpose of the present study was therefore to test the 
hypotheses that CaMK II activation by caffeine: a) causes hyperacetylation of histones in the 
neighbourhood of the NRF-1 binding site on the mef2a gene, b) increases mef2a-bound NRF-1, and 
c) increases MEF2A transcription. 
5.2. Methodology 
 
         5.2.1. Treatment of myotubes: C2C12 myotubes, which were allowed to differentiate in 
medium containing 2 % horse serum for 9-13 days, were treated with 10 mM caffeine for 2 h and 
harvested at 0, 3, 6, 9, 12 or 18 h post treatment. The level of phosphorylated CaMKII (pCaMK II) 
and total CaMK II were assayed by western blot. For ChIP and qRT-PCR analysis, myotubes were 
treated with 10 mM caffeine or 10 mM caffeine + 25 μM KN93, for 2 h and harvested 6 h later. For 
MEF2A protein assessment, myotubes were treated with 10 mM caffeine or 10 mM caffeine + 25 μM 
KN93 for 2 h per day for 4 days. Untreated cells served as controls in all cases. 
5.2.2. Western Blot. After the treatments, myotubes were washed 2x with PBS, scraped loose 
form the culture plate in 300 µl RIPA buffer (56 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 
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0.1 % SDS, 1 % Triton-X100, 10 mM Na4P2O4, 20 mM NaF, 0.15 μM okadaic acid, 4 mM Na3VO4, 
1 x complete protease inhibitors) and homogenized using a dounce homogenizer. The contents of 
pCaMK II, CaMKII, MEF2A and α-tubulin in the crude extracts were measured by western blot as 
described previously in Section 3.7.3. 
5.2.3. ChIP assay:  ChIP assay was used to measure the amount of NRF-1 that was bound to 
its cis element on the mef2a gene and the extent of acetylation of histone H3 in the neighbourhood of 
this domain. Briefly, myotubes were fixed with formaldehyde, sonicated to fragments of 300-1000 
DNA bp and the chromatin fragments immunoprecipitated using anti-NRF-1 (Abcam), anti-acetyl 
histone H3 or anti-histone H3 antibodies (Cell signalling). IgG (Cell signalling) was used as a 
negative control antibody in all cases. Co-immunoprecipitated DNA was PCR amplified using 
primers that recognize the NRF-1 sites on the mef2a gene. Control primers that targeted regions 
which do not contain the NRF-1 binding site on the mef2a gene, were also used as negative controls. 
PCR products were electrophoresed on 2 % agarose gels and the sizes of resulting bands quantified 
by densitometry.  Signals from immunoprecipitated chromatin (IP) were normalised to corresponding 
input (chromatin that did not undergo immunoprecipitation) signal (IN). The assay protocol is 
described in detail in Section 3.9.1-3  
   5.2.4. Quantitative RT-PCR. After treatments, total RNA from harvested myotubes was 
extracted using 1 ml Trizol as described in Section 3.10.2. One μg of RNA was mixed with 0.5 μg of 
22-mer oligo-dT primer and incubated at 70 
o
C for 5 min to denature RNA secondary structures. 
Genomic DNA was eliminated from the samples by digestion with 1 U DNAse-1 (Promega) for 90 
min at 37 
o
C and DNAse-1 was subsequently deactivated by incubation at 75 
o
C for 5 min. cDNA 
was synthesized using 200 U of M-MLV reverse transcriptase (Promega) for 1 h at 42 
o
C. 
Quantitative real time PCR (qRT-PCR), using 1 l cDNA, was performed to measure MEF2A 
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mRNA by a Light Cycler PCR machine (Roche) using SYBR Green PCR reagents (Roche) and 
primers which amplify a 187 bp region of the mouse mef2a gene (see  table 3.5). The concentration 
of MEF2A mRNA relative to GAPDH or Ribosome S12 (internal controls) were calculated using the 
method described by Livak & Schmittgen (140) and mean values of the triplicate samples were 
normalized to the mRNA level of a control untreated sample (see Section 3.10.2.) 
5.3. Results  
           5.3.1. Caffeine activates CaMK II in C2C12 myotubes. It is widely accepted that CaMK II 
activation is achieved via phosphorylation (34; 82; 131; 141). To verify that caffeine activated CaMK 
II in C2C12 myotubes, we measured the level of phosphorylation of CaMK II at Thr286 (pCaMK II) 
at 0, 3, 6, 9, 12 and 18 h after 2 h treatment with 10 mM caffeine. Total CaMK II was also measured 
at these time points for comparison (Fig 5.1B). Figures 5.1A and B, showing the graph and western 
blot of pCaMK II for these time points, indicates that immediately after caffeine treatment (0 h) 
pCaMK II level was ~3.5-fold higher than control values and declined progressively thereafter. Total 
CaMK II content remained constant at all time points. These results indicate that 10 mM caffeine 
activated CaMK II in the myotubes.  
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Figure 5.1: Phosphorylation of CaMK II in C2C12 myotubes after treatment with caffeine.  A: Quantitative analysis 
of pCaMK II relative to total CaMK II from myotubes that were treated for 2 h with caffeine and analysed at time points 
0-18 h post treatment. Signals were nomalized to control (without caffeine treatment).  * P = 0.001 vs control. B: Western 
blot of the contents of pCaMK II and total CaMK II levels before and after caffeine treatment (0-18 h). pCaMK II signal 
was normalized to total CaMK II. N=3. *P<0.05. Data presented as means ± SD.  
  
5.3.2. CaMK II activation increases NRF-1 binding to the mef2a promoter in C2C12 
myotubes. Although previous studies have shown that activation of CaMK II by caffeine increases 
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MEF2A content in myotubes (173), the mechanism(s) involved have not been identified. Our 
observation, reported in the previous chapter, that increased binding of NRF-1 to the mef2a gene is 
associated with MEF2A expression, led us to suspect that CaMK II activation by caffeine might 
increase MEF2A expression via increased NRF-1 binding to the mef2a promoter. To test this 
hypothesis, we incubated C2C12 myotubes with caffeine in the presence or absence of KN93 for 2 h 
and measured the content of mef2a promoter-bound NRF-1 6 h post treatment using ChIP assay. The 
gel in Figure 5.2 shows a typical pattern of PCR products from immunoprecipitated (IP) and input 
(IN) samples. The ratio of signal intensities between IP and IN for each treatment was normalized to 
control and is depicted graphically in Figure 5.2. As shown, caffeine caused ~2.5–fold increase in the 
amount of NRF-1 that bound to the mef2a promoter; and incubation of myotubes with 25 M KN93 
abolished the effect of caffeine. These results indicate that caffeine increases NRF-1 binding to the 
mef2a promoter via a CaMK II- dependent mechanism.  
  The specificity of the ChIP assay was verified by the following observations: a) there was no 
evidence of NRF-1 binding at the mef2a coding region in position +2904 - +3154 which has no NRF-
1 binding element as indicated in Chapter 3 (Figure 3.12), b) only the anti-NRF-1, but not IgG, was 
able to co-immunoprecipitate the MEF2A binding domain (Fig 3.12 lanes 2 and 3 respectively).    
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Figure 5.2: CaMK II activation increases NRF-1 binding to the mef2a gene in C2C12 myotubes. Myotubes were 
treated with 10 mM caffeine in presence or absence of KN93 for 2 h and chromatin immunoprecipitation determined 6 h 
post incubation PCR signals for ChIP assay to detect the levels of NRF-1 binding to the mef2a gene assessed from IP 
(immunoprecipitation) samples were normalized to IN (Input) samples as shown below the graph. The bars represent the 
IP/IN ratio normalized to control. * P = 0.003 vs Control, * P = 0.009 vs Caf+KN93, *P = 0.001 vs KN93. N = 4. * 
P<0.05. Data represented as means ± SD. 
 
  
             5.3.3. CaMK II activation induces hyper-acetylation of histones at the neighbourhood of 
the NRF-1 binding site on the mef2a promoter. It is now well established that CaMK activation 
induces nuclear export of HDACs in a variety of cell types (143; 158). A decrease in HDAC nuclear 
content has been shown to induce hyperacetylation of histones in nucleosomes because the level of 
acetylation of histones in nucleosomes is dependent on the balance between the activities of HATs 
and HDACs (13). Because binding of transcription factors to DNA in vivo is enhanced by hyper-
acetylation of histones in close proximity to their binding domains (168), we reasoned that the 
increase in mef2a-bound NRF-1 that we observed after caffeine treatment might be associated with 
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hyperacetylation of histones in the neighbourhood of the NRF-1 binding site on the mef2a promoter 
region. To test this view, we measured the contents of acetyl histone H3 in the region which 
encompasses the NRF-1 binding site at the mef2a promoter by ChIP assay in C2C12 myotubes that 
were treated with caffeine in the presence or absence of KN93. Representative agarose gels showing 
PCR products from control, caffeine, and caffeine + KN93 -treated myotubes are shown in figure 5.3 
A. Signals from input (IN) sample, representing the total NRF-1 site in the sample, and from 
immunoprecipitated (IP) samples, representing the fraction that contain acetylated H3 histones, are 
shown adjacent to each other (for each treatment group) to facilitate comparison. The fraction, IP 
NRF-1 site/Total NRF-1 site (i.e acetylated histone/histone H3), which represent the relative levels of 
H3 acetylation under different treatments, are graphed in figures 5.3 B & C. The data shows that 
caffeine treatment increased the level of acetylation of histone H3 in the vicinity of the NRF-1 site on 
the mef2a promoter compared to control, but the increase was abolished by KN93. 
 Because acetylation of histones remodels chromatin, it may be argued that the observed 
differences in signal intensities from the various treatments were due to inequalities in cross-linking 
efficiencies or antibody accessibility to histones. Therefore, we performed control experiments using 
an antibody against histone H3 (Cell signalling). As can be seen from Figure 5.3 C (histone H3), the 
signal intensity was similar in all treatments when this antibody was used; demonstrating that there 
were no differences in cross-linking efficiencies and/or antibody accessibility.  
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Figure 5.3: Acetylation of histone H3 in the neighbourhood of NRF-1 site on the mef2a gene. Caffeine induced an 
increase in acetylation of NRF-1 sites on the mef2a genes in C2C12 myotubes. Myotubes were treated with 10 mM 
caffeine (caf) in the presence or absence of KN93 for 2 h and chromatin immunoprecipitation determined 6 h post 
incubation. A: Shows gels for acetylation of histones on the neighbourhood of NRF-1 binding sites on the mef2a 
promoter with AcH3 (acetylated H3) and histone H3 control experiment. Bar graph representing acetylated histone H3 
(AcH3) * P = 0.001 vs Control, * P = 0.007 vs Caf+KN93, and histone H3 are shown in B and C, respectively. N = 4. * 
P<0.05. Data represented as means ± SD. 
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5.3.4. Caffeine increases MEF2A expression in a CaMK II-dependent manner: It has 
previously been shown that chronic treatment of L6 myotubes with caffeine increased MEF2A 
content in L6 myotubes in a CaMK II-dependent manner (173). Our observation of increased binding 
of NRF-1 to the mef2a promoter in C2C12 myotubes caused us to suspect that the increased level of 
MEF2A that is seen after caffeine treatment results from increased transcription. We therefore 
measured MEF2A mRNA at 6 h post incubation by qRT-PCR. Figure 5.4A shows that MEF2A 
mRNA was increased ~2-fold by caffeine relative to control. Inclusion of KN93 in the medium 
together with caffeine prevented the increase in MEF2A mRNA; suggesting that the increase in 
MEF2A mRNA is also CaMK II driven. GAPDH did not change under the experimental conditions 
used. Consistent with previous observation in L6 myotubes, incubation of C2C12 myotubes with 
caffeine for 2 h per day for 4 days increased MEF2A protein ~2-fold, and inclusion of KN93 in the 
medium abolished the increase due to caffeine (Fig 5.4B).  
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Figure 5.4: CaMK II activation increases MEF2A mRNA and protein levels in C2C12 myotubes. Myotubes were 
treated with 10 mM caffeine in the presence or absence of KN93 (Caf +KN93). A: MEF2A mRNA was measured by 
quantitative RT-PCR as described in experimental procedure. Well differentiated myotubes were treated for 2 h and cells 
harvested 6 h post treatment ( * P = 0.001 vs Control & Caf+ KN93). B: Western blot showing MEF2A protein levels. 
Myotubes were treated for 2 h for 4 days with caffeine in the presence or absence of KN93 (Caf + KN93). The bars 
represent relative units normalized with the control (*P = 0.02 vs Control, * P = 0.009 vs Caf+KN93). (N=4). * P<0.05. 
Data represented as means ± SD. 
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5.4. Discussion and Conclusion 
 
The main findings from the present study are that CaMK II activation by caffeine increased: 
a) MEF2A expression, b) the level of acetylation of histone H3 in the vicinity of the NRF-1 binding 
site on the mef2a promoter and c) mef2a promoter- bound NRF-1. Ramachandran et al. (185) recently 
provided overwhelming evidence that NRF-1 is a key regulator of mef2a gene expression when they 
showed that: a) the 5‟ mef2a regulatory region within ~0.8 kb upstream of the transcription start site, 
which is highly conserved among mammals, contains MEF2, NRF-1 and E-box elements, b) 
endogenous NRF-1 binds to the mef2a promoter element, c) MEF2A mRNA was strongly induced in 
cells that overexpressed NRF1VP16 (NRF-1 fused to the trans-activating domain from viral VP16), d) 
mef2a promoters are highly responsive to forced expression of NRF-1 or NRF1VP16 in mammalian 
(HeLa) and Drosophila  cells and e) myocyte mef2a mRNA is reduced with nrf-1 interference. Our 
finding that, CaMK II influences the acetylation state of histones in the region encompassing the 
NRF-1 binding domain on the mef2a gene, adds new insights onto the mechanism of mef2a gene 
regulation by NRF-1: It supports the hypothesis that CaMK II activation remodels chromatin to 
favour increased accessibility of NRF-1 to its binding domain on the mef2a gene to favour mef2a 
transcription.  
The level of acetylation of histones in nucleosomes depends on the balance between the 
activities of HATs, which acetylate histones, and HDACs, which remove acetyl groups from 
histones. There is a growing body of evidence showing that CaMK II phosphorylates class II histone 
deacetylases, such as HDAC4 and HDAC5, and induces their nuclear export (143; 156; 158). 
Decreased nuclear HDAC content due to CaMK II activation would favour increased nuclear HATs 
activity resulting in hyperacetylation of histones in nucleosomes and enhanced accessibility of 
transcription factors to their binding domains on DNA. There is also evidence that some HATs, e.g. 
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p300, are substrates of CaMK II: Yuan et al, (239) have shown that p300 is phosphorylated and 
activated when acted upon by CaMK II. Our observation, of ~2.5-fold increase (compared to control) 
in the level of acetylation of histone H3 surrounding the NRF-1 binding domain on the mef2a gene, 
and a similar increase in the the content of mef2a-bound NRF-1, provide evidence that these effects 
of CaMK occur at the mef2a promoter region. However, the effect of CaMK activation by caffeine on 
nuclear HDAC content has not been studied, nor is the species of HDAC that are affected known. 
Moreover, the specific HAT that is responsible for hyperacetylation of histones surrounding the 
NRF-1 binding domain has not yet been identified, although p300 and cyclic AMP response element-
binding (CREB) protein associated factor (CAF) are likely candidates because they are capable of 
acetylating all four histones (14; 171) and have been shown to associate with NRF-1 and MEF2 (89; 
110; 147; 198). 
Although our data clearly show that CaMK II activation caused hyperacetylation of histone 
H3 on the region encompassing NRF-1 binding site on the mef2a promoter and increased NRF-1 
binding to the site, we are unable to conclude that the increased binding was due to the observed 
histone hyperacetylation. Other factors, such as increased NRF-1 acetylation, may have contributed 
to the increased binding. Indeed, Izumi et al., (110) showed that treatment of human breast cancer 
cells (MCF-7) with sodium butyrate increased NRF-1 binding activity via increased acetylation of 
NRF-1 at the N-terminal domain (which contains 17-clustered lysine residues) by p300/CAF 
associated factor (110). The observed CaMK II inhibition by KN93 on caffeine-induced: a) 
hyperacetylation of histones surrounding the NRF-1 binding sites on the mef2a promoter, b) increase 
in NRF-1 binding to the mef2a promoter and c) increase in MEF2A protein expression, does not 
exclude the possibility that other non-CaMK II stimuli (such as AMPK which has a similar substrate 
specificity to CaMK II) may have been involved in these processes. 
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Consistent with previous observations in L6 myotubes (173), we have shown in the present 
study that caffeine also increases MEF2A expression in C2C12 myotubes. Because the increase in 
MEF2A expression was blocked when KN93 was included in the medium together with caffeine, it 
follows that the increase in MEF2A expression by caffeine is CaMK II-driven. Our finding that 
CaMK activation increased MEF2A expression is consistent with findings from several other studies: 
Passier et al., (176) showed that CaMKIV overexpression in the heart resulted in >100-fold increase 
in MEF2A expression (176). Likewise, Zhang et al., (241) found that CaMK II activation in 
cardiomyocytes induced ~ 7-fold increase in MEF2 gene expression. The increase in MEF2A content 
appears to affect the expression of glut4 and some mitochondrial genes: With regard to glut4 gene, 
Smith et al., (212) showed that CaMK II activation by exercise resulted in increased MEF2A binding 
to the glut4 gene and ~2-fold increase in GLUT4 expression. Activation of CaMK II with caffeine 
also increased GLUT4 expression (173) and mitochondrial proteins such as δALAS, citrate synthase, 
cyclooxygenase-1 (COX-1) and cytochrome c (172) in L6 myotubes.  Incubation of L6 myotubes 
with A23187, a Ca
2+
 ionophore which increases cytosolic Ca
2+
 levels and activates CaMK II (173) 
increases the expressions of malate dehydrogenase F1-ATPase and cytochrome c (58). Transgenic 
mice that selectively express a constitutive active CaMKIV in skeletal muscle have increased 
expression of enzymes involved in fatty acids metabolism and electron transport chain (234). Given 
that many of these mitochondrial enzymes, are encoded by genes that are regulated by NRF-1, we 
speculate that CaMK activation might have caused hyperacetylation of histones at NRF-1 binding 
sites on these mitochondrial genes and increased NRF-1 binding to these sites.  
Several studies have shown that exercise increases MEF2A expression (54; 227). Although 
the mechanism responsible has not been investigated, the findings from the present study lead us to 
speculate that it might be CaMK II driven. Indeed, several studies have shown that exercise activates 
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CaMK II (6; 55; 57; 193-195). Furthermore, since CaMK II activation by caffeine induces histone H3 
hyperacetylation in the region surrounding the NRF-1 binding site, we are led to speculate that 
exercise might also induce histone hyperacetylation and increase NRF-1 binding in the same region. 
These speculations remain to be tested empirically. 
In summary, our results shed new insights on CaMK‟s involvement in the regulation of 
MEF2A expression by NRF-1. We have demonstrated that CaMK II activity is necessary for NRF-1 
binding to the mef2a gene and is associated with increased acetylation of histones surrounding the 
NRF-1 binding sites on the mef2a promoter. 
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Chapter 6 
Study 3: 
CaMK II activation exports HDAC5 from the nucleus and induces hyperacetylation of histones 
in the vicinity of the MEF2 cis-element on the glut4 promoter in C2C12 myotubes 
6.1. Introduction  
 
Previous studies have reported that CaMK activation regulates GLUT4 expression. For 
example, Ojuka et al., (173) activated CaMK II in C2C12 myotubes using caffeine and observed ~2-
fold increase in GLUT4 content. Jensen et al., (114) also showed that mice that expressed 
constitutively active CaMKIV had 30 % higher GLUT4 in skeletal muscle. Although the mechanism 
through which CaMK II regulate glut4 expression has not been investigated, it is well known that 
GLUT4 expression is regulated by the binding of MEF2 to its consensus binding element on the glut4 
promoter (223). Therefore we reasoned that CaMK II activation might increase GLUT4 by improving 
the easy with which MEF2 factors bind to the glut4 promoter. 
There are four isoforms of MEF2 transcription factors, namely MEF2A, MEF2B, MEF2C and 
MEF2D. All of these isoforms possess a signature domain that specify MEF2 binding to a highly 
conserved AT-rich sequence [CTA(T/A)4TAG] found in human, rat and mouse glut4 gene (18; 139). 
It is reported that MEF2A binds to the glut4 gene as a heterodimer with MEF2D (223) and when 
bound they recruit other transcriptional regulators such as p300/CBP (210), PGC-1 (160), GLUT4 
enhancer factor (GEF), and MAPK such as p38 (80; 158; 160). The multimeric transcriptional 
complex that forms around MEF2 then attracts and activates RNA polymerase II, which initiates the 
glut4 gene transcription.  
Un
ive
rsi
ty 
Of
 C
ap
 To
wn
 
  
94 
 
MEF2 transcription factors also interact with Class II HDACs such as HDAC4 and 5 (143; 
158) and HATs (49; 198; 210). Association of HDACs with MEF2 appears to suppress GLUT4 and 
other MEF2-dependent transcription (158; 214). For example, McGee & Hargreaves (156) reported a 
strong reverse correlation between nuclear MEF2A/HDAC content and GLUT4 mRNA and Czubryt 
et al., (40) showed that expression of a mutant form of HDAC5 which constitutively localizes in the 
nucleus results in a 3-fold decrease in GLUT4 expression. Stimuli such as exercise or overexpression 
of CaMK IV have been shown to dissociate MEF2A/HDAC complexes and induce export of HDACs 
out of the nucleus to the cytoplasm (143; 156). This nucleo-cytoplasmic shuttling of HDACs, which 
is dependent on phosphorylation of two serine motifs on HDACs by CaMKs, seem to promote 
association of MEF2 factors with HATs (41; 79; 237) and de-repressed MEF2-dependent genes 
(143). Indeed it is now known that the binding site of HDAC5 on MEF2 overlaps that of HAT 
p300/CPB; suggesting that dissociation of HDAC5 from MEF2 allows the association with 
p300/CBP (49; 143; 198). HATs acetylate histones, which relaxes chromatin and promotes 
transcription by increasing the accessibility of binding domains for transcriptional factors and other 
transcriptional regulators.  
Because caffeine has been shown to activate CaMK II (see section 5.3.1) and increase 
GLUT4 expression (173) in L6 myotubes, we hypothesised that caffeine would: a) induce HADC5 
nuclear export,  b) promote hyperacetylation of histones on the MEF2 binding site on the glut4 gene, 
and c) increase binding of MEF2A to the glut4 promoter. To test these hypotheses, we incubated 
C2C12 myotubes with caffeine in the presence or absence of KN93 or dantrolene and assessed: a) 
HDAC5 abundance in the nucleus and cytosol, b) acetylation of histone H3 in the vicinity of the 
MEF2 site on the glut4 promoter, c) the extent to which MEF2A was bound to its cis element on the 
GLUT4 promoter, and e) GLUT4 expression. 
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 6.2. Methodology 
 
           6.2.1. Treatment of myotubes: C2C12 myoblasts were cultured in DMEM containing 2 % 
horse serum for 13 days to form well differentiated myotubes. They were then incubated for 2 h in 
medium containing10 mM caffeine, 10 mM caffeine +25 μM KN93, or 10 mM caffeine +10 μM 
Dantrolene. After treatment, they were harvested immediately or after 6 h for immunocytochemical 
analysis or for ChIP and qRT-PCR assays, respectively. For assessment of the effects of these 
treatments on the contents of HDAC5, MEF2A, GLUT4 and α-tubulin, myotubes were treated for 2 h 
per day for 4 consecutive days and harvested 18 h after the last treatment. Untreated myotubes served 
as controls in all cases. 
6.2.2. Western Blot: After treatments, myotubes were washed 2x with PBS, scraped loose 
form the culture plate in 300 µl RIPA buffer (56 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 
0.1 % SDS, 1 % Triton-X100, 10 mM Na4P2O4, 20 mM NaF, 0.15 μM okadaic acid, 4 mM Na3VO4, 
1 x complete protease inhibitors) and homogenized using a dounce homogenizer. Total, nuclear and 
cytosolic proteins were extracted as described in section 3.7 and the protein content in each 
component measured using the Bradford assay. The activity of LDH (Santa Cruz), and the contents of 
-tubulin and histone H3, was measured in both nuclear and cytosolic extracts to ascertain that our 
method effectively separated the nuclear and cytosolic compartments. The contents of HDAC5, 
MEF2A, GLUT4 and α-tubulin in the crude and nuclear extracts were measured by western blot as 
described previously in Section 3.7.3.  
           6.2.3. Immunocytochemistry analysis: Immediately after treatments, myotubes
 
were washed 
in ice-cold PBS and fixed with 3:1 methanol/glacial
 
acetic acid at –20 °C for 10 min. Thereafter, they 
were washed in PBS, blocked in 1 % BSA for 30 min, and incubated
 
overnight at 4 °C with 
antibodies against HDAC5 (Sant Cruz) and MEF2A (Cell signalling).
 
The following day, cells were 
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washed and incubated with fluorochrome-conjugated
 
anti-rabbit (Cy3) and goat anti-mouse (Alexa) 
secondary antibodies
 
(diluted 1:1000) for 2 h at room temperature. Nuclei were stained
 
with a 1:50 
dilution of 0.05 µg/ml DAPI for 10 min at
 
room temperature. After being washed, a coverslip was 
mounted
 
on the cells with a solution consisting of 40 % glycerol, 20 %
 
Mowiol, 8 % n-propyl gallate, 
and 0.2 M Tris buffer (pH 7.4). Subcellular location of HDAC5 and MEF2A was viewed using a 
Zeiss
 
Axiovert 200M fluorescence microscope equipped with plan-neofluar
 
optics set at 15 (Cy3), 10 
(Alexa 488), and 1 (DAPI) as well
 
as an Axiocam HR charge-coupled device camera. Adobe 
Photoshop
 
7 software was used for image processing. 
            6.2.4. ChIP assay:  In order to measure the content of MEF2A that was bound to its binding 
sequence on the glut4 gene and the extent of acetylation of histone H3 in the neighbourhood of the 
MEF2A binding domain on the glut4 gene, ChIP assays were used. Briefly, myotubes were fixed 
with formaldehyde, sonicated to fragment the chromatin to 300-1000 bp and the chromatin fragments 
co-immunoprecipitated using anti-MEF2A, anti-acetyl histone H3 or anti-histone H3 antibodies (Cell 
signalling). IgG (Cell signalling) was used as a negative control antibody. Co-immunoprecipitated 
DNA was PCR amplified using primers that recognize a sequence with the MEF2A sites on the glut4 
gene (refer to Section 3.9.3.3). Control primers that targeted regions which do not contain the 
MEF2A binding site on the glut4 gene, were also used as negative controls. PCR products were 
separated by electrophoresis on a 2 % agarose gel and the signals quantified by densitometry. Signal 
from the immunoprecipitated chromatin (IP) was normalised to its corresponding input (chromatin 
that did not undergo immunoprecipitation) signal (IN). The assay protocol is described in detail in 
Section 3.9.1-3.  
         6.2.5. Quantitative RT-PCR: After treatments, total RNA from myotubes that were harvested 
from 10 cm plate was extracted using 1 ml Trizol (Ambion) as described in Section 3.10.2. One μg of 
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RNA was mixed with 0.5 μg of 22-mer oligo-dT primers and incubated at 70 oC for 5 min to denature 
RNA secondary structures. Genomic DNA was eliminated from the samples by digestion with 1 U 
DNAse-1 (Promega) for 90 min at 37 
o
C. DNAse-1 was subsequently deactivated by incubation at 75 
o
C for 5 min. cDNA was synthesized using 200 U M-MLV reverse transcriptase (Promega) for 1 h at 
42 
o
C and stored at -20 
o
C. Quantitative real time PCR (qRT-PCR), using 1 l cDNA, was performed 
to measure GLUT4 mRNA by a Light Cycler PCR machine (Roche) using SYBR Green PCR 
reagents (Roche) and primers which amplify a 270 bp region of the mouse GLUT4 gene (see  table 
3.5). The concentration of GLUT4 mRNA relative to GAPDH or Ribosome S12 (internal controls) 
were calculated using the method described by (291) and mean values of the triplicate samples were 
normalized to the mRNA level of a control untreated sample (see Section 3.10.2.) 
6.3. Results  
 
6.3.1. CaMK II activation by caffeine induces HDAC5 nuclear export. It has previously 
been shown that expression of constitutively active CaMK IV in fibroblasts (10T1/2) and Cos cells 
caused nuclear export of HDAC5 and stimulated MEF2-dependent differentiation of these cells. 
These observations led us to suspect that CaMK II activation by caffeine might also induce HDAC5 
nuclear export in differentiated myotubes. To confirm this suspicion, we performed 
immunocytochemical studies on HDAC5 and MEF2A proteins to determine if caffeine affected their 
localization within myotubes via a Ca
2+
-dependent activation of CaMK II.  
C2C12 myotubes were incubated for 2 h with 10 mM caffeine in the presence or absence of 
10 M dantrolene or 25 M KN93. Representative images from immunocytochemical analysis and 
western blot are shown in figures 6.1 A and B, respectively. Immunocytochemical images revealed 
that MEF2A was located predominantly
 
in the nucleus under all conditions, i.e. in untreated cells and 
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in caffeine-treated cells in the absence or presence of dantrolene or KN93 (Fig. 6.1A: panels D, L and 
P). In
 
contrast, whereas HDAC5 was found in both the nucleus and the cytosol
 
in untreated cells, 
incubation with caffeine caused a decrease
 
in intra-nuclear but an increase in peri-nuclear HDAC5 
density
 
(Fig 6.1A; G). Inclusion of KN93 or dantrolene in the medium together with caffeine blocked 
the effect of caffeine (Fig. 6.1A: panel I-L
 
and M-P). These results provide evidence that caffeine
 
causes HDAC5 to traffic out of the nucleus in a calcium- and
 
CaMK II-dependent manner. Western 
blot of HDAC5 and MEF2A form nuclear extracts (Figure 6.1 B) confirmed the observations from 
immunocytochemical analyses. Caffeine
 
reduced the nuclear contents of HDAC5 (P < 0.05) but not 
MEF2A, resulting in a diminished HDAC5/MEF2A ratio, compared with
 
untreated controls (Fig. 
6.1B). Inclusion of dantrolene or KN93 together
 
with caffeine attenuated the decreases in nuclear 
HDAC5 content
 
and HDAC5/MEF2A ratio.  
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Figure 6.1: Representative Immunocytochemical images and western blot showing the localization of HDAC5 and 
MEF2A in C2C12 myotubes. A: After incubation in medium containing 10 mM caffeine (Caf) in the presence or 
absence of 10 µM dantrolene (Dan)  or 25 µM KN93 for 2 h, subcellular localization of the nucleus, HDAC5, and 
MEF2A was determined using the immunocytochemical technique described in section 3.8.3. A–D: control untreated 
myotubes. E–H: myotubes incubated with 10 mM caffeine.I-L: myotubes treated with caffeine+25 µM KN93. M-P: 
myotubes incubated with caffeine+10 mM dantrolene. Blue: 4, 6-diamidino-2-phenylindole (DAPI) nuclear stain; red, 
HDAC5; green, MEF2A. Arrows indicate decreased intranuclear HDAC5 and arrowheads increased perinuclear HDAC5 
levels. Scale bar, 10 µm. N = 4. B: Western blot analysis of nuclear contents of MEF2A and HDAC5. Representative 
western blots of MEF2A and HDAC5 from nuclear extracts and a histogram of the HDAC5/MEF2A ratio for the various 
treatments. The histogram reflects the abundance of HDAC5 relative to MEF2A in the nucleus. *P = 0.002 vs. Control, * 
P = 0.005 vs Caf+KN93 & Caf+Dan; n = 5 independent experiments. Data represented as means ± SD. 
 
6.3.2. CaMK II activation induces hyperacetylation of histones at the MEF2A site on the 
glut4 promoter. The level of nucleosomal acetylation results from the balance between the activities 
of HDACs, which removes acetyl moieties from histones proteins and HATs which adds the acetyl 
groups to the histones. The CaMK II-driven nuclear export of HDAC5 that was observed (Fig 6.1) 
suggested to us that that nuclear HAT activity might be increased and prompted us to check if the 
level of acetylation of histones in the vicinity of the MEF2 binding element on the glut4 promoter 
was increased. Figure 6.2A and 6.2B shows ChIP assay results for various treatment groups 
following immunoprecipitation by antibodies directed against acetylated histone H3 and histone H3. 
Signals from input sample (IN), representing the total MEF2 binding sites in the sample, and from 
immunoprecipitated samples (IP), showing the fraction of the sites that contained acetylated histone 
H3, are shown adjacent to each other (for each treatment group) to facilitate comparison. The 
fraction, IP /IN, which represents the levels of acetylation of histones in the vicinity of the MEF2A 
binding domain under different treatments, is depicted in Fig. 6.2 B. Here we see that caffeine 
treatment increased the amount of AcH3 (acetylated histone H3) in the vicinity of MEF2 cis-element, 
but this effect of caffeine was abolished by dantrolene or KN93. Differences in cross-linking 
efficiencies and in the accessibility of antibody to histones that may result from the treatments can 
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influence the interpretation of ChIP assay results. To check if such differences existed in our 
experiments, we conducted control experiments using an antibody against histone H3. As depicted in 
Fig. 6.2A and 6.2C, ChIP assay results were similar in all treatment groups: Indicating that there were 
no differences in cross-linking efficiencies and/or antibody accessibility in our protocol. In summary, 
our results confirm that caffeine increases a) the binding of MEF2A to the glut4 promoter and b) 
acetylation of histone H3 in the vicinity of the MEF2A site on the glut4 promoter in a calcium- and 
CaMK II-dependent manner.  
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Figure 6.2: Caffeine induced hyperacetylation of histone H3 at the MEF2A site on the glut4 promoter in a calcium 
and CaMK II dependent manner. Myotubes were treated with 10 mM CAF (caffeine) in the presence and absence 10 
µM DAN (Dantrolene) or 25 µM KN93 for 2 h. The level of acetylation of histone H3 at the MEF2A binding site on the 
glut4 promoter by chromatin immunoprecipitation assay 6 h post incubation. A: a section of the glut4 promoter spanning 
the MEF2A binding site was PCR amplified from DNA that was coimmunoprecipitated (IP) with acetylated histone H3 
(AcH3) or histone H3 antibody and from corresponding input (IN) samples. B: relative amounts of acetylated histones at 
the MEF2A site on the glut4 gene C: relative amounts of non-acetylated H3 at the MEF2A site. The bars represent the 
IP/IN ratio normalized to control, * P = 0.001 vs Caf+KN93, * P = 0.006 vs Caf+Dant, * P = 0.009 vs KN93 & Dant. *P 
< 0.05 vs. control. M: molecular weight marker. Data represented as means ± SD. N=4. 
 
  6.3.3. CaMK II activation increases MEF2A binding to the glut4 gene. Hyperacetylation of 
histones is associated with increased accessibility of transcriptional factors to their DNA binding 
domains and the recruitment of transcriptional regulators to the site. Since we observed increased 
acetylation of histones on the neighbourhood of MEF2 binding domain on the glut4 promoter, we 
assessed the level of MEF2A that was bound to the site. Figure 6.3 shows typical agarose gel of the 
268 bp DNA that was PCR amplified from DNA that was co-immunoprecipitated with MEF2A 
antibody (IP) and DNA from input sample. The graph shows the signals after they were quantified by 
densitometry. Caffeine increased the glut4-bound MEF2A by ~2.3-fold compared with controls. 
However, when CaMK II activity was blocked by KN93, the amount of bound MEF2A was 
attenuated significantly. Moreover, when dantrolene was used to block caffeine-induced increases in 
cytosolic calcium (173), the increase in glut4-bound MEF2A was also blocked; implying that the 
increase in glut4 bound MEF2A depends on Ca
2+
-dependent CaMK II activation.  
The specificity of the ChIP assay was verified by the following observations: a) there was no 
evidence of MEF2A binding at the glut4 coding region in position +2868- +3183 which has no 
MEF2A binding element as indicated in the previous chapter 3 (Figure 3.13), b) only the anti-
MEF2A, but not IgG, was able to co-immunoprecipitate the glut4-MEF2 binding domain (Fig 3.12 
lanes 2 and 3 respectively).   
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Figure 6.3: CaMK II activation induces an increase in the binding of MEF2A to the glut4 promoter. Myotubes were 
treated with 10 mM caffeine (Caf) in the presence and absence 10 µM Dant (dantrolene) or 25 µM KN93 for 2 h and 
ChIP assay performed 6 h later. Relative amounts of glut4 promoter-bound MEF2A was calculated from signal densities 
from PCR reactions in both IN and IP. The bars represent the IP/IN ratio normalized to control. * P = 0.0011 vs Control, 
* P = 0.005 vs Caf+KN93, * P = 0.009 vs Caf+Dant. N=4. Data represented as means ± SD. *P<0.05. 
 
6.3.4. CaMK II activation increases GLUT4 mRNA and protein. After observing increased 
acetylation of histones and MEF2A binding to the glut4 promoter, we next assessed the level of 
GLUT4 expression. We treated C2C12 myotubes with 10 mM caffeine or vehicle for
 
2 h and 
harvested the cells 6 h later for GLUT4 mRNA measurement. We found that CaMK II activation 
resulted in increased GLUT4 mRNA by 2.6-fold
 
(P < 0.05; Fig 6.4A); however GAPDH did not 
change under all experimental conditions. In myotubes that had been treated for 2 h for 4 consecutive 
days, GLUT4 protein was ~2.7-fold higher compared to controls. The caffeine-induced increases in 
GLUT4
 
mRNA and protein were significantly reduced when caffeine and KN93 were included in the 
growth medium; indicating that these increases require CaMK II. 
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Figure 6.4: GLUT4 protein and mRNA is increased by caffeine (CAF) in C2C12 myotubes. Well-differentiated 
myotubes were incubated with 10 mM CAF in the presence or absence of 25 µM KN93 or 10 µM dantrolene (DAN) in 
serum-free medium for 2 h. A. Myotubes were harvested 6 h after the last treatment. GLUT4 mRNA was measured by 
real-time PCR as described in experimental procedures. * P = 0.0015 vs Control, * P = 0.001 vs Caf+KN93.  B. Western 
blot for GLUT4 protein from myotubes that were treated for 2 h per day for 4 consecutive days. Data represented as 
means ± SD. N=6. *P < 0.05. 
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6.5. Discussion and Conclusion 
 
Previous studies have shown that CaMK II regulates GLUT4 expression in L6 myotubes 
(173). The current study was designed to explore the mechanism involved. Here, we present evidence 
that CaMK II activation with caffeine: a) exports HDAC5 from the nucleus, b) induces 
hyperacetylation of histones on the neighbourhood of MEF2 domain on the glut4 promoter, c) 
increases MEF2A binding to the glut4 promoter, and d) increases GLUT4 expression. All the above 
changes were attenuated by inclusion of KN93 or dantrolene in the medium, indicating that these 
changes occur via a Ca
2+
- and a CaMK II-dependent pathway.  
Acetylation of histones by HATs, and deacetylation by HDACs are recognized as important 
opposing mechanisms in controlling gene expression (130). Normally genes are expressed when 
surrounding histones are hyperacetylated, a process which is facilitated by HATs (217). They are 
normally repressed when surrounding histones are deacetylated by HDACs (130). In this study we 
have found that histone H3 in the vicinity of the MEF2A binding site on the glut4 promoter were 
hyperacetylated when caffeine was used to activate CaMK II in C2C12 myotubes and hypoacetylated 
when KN93 was included in the medium together with caffeine to inactivate CaMK II. This finding 
indicates that CaMK II increases the activity of some HAT which acetylates histone H3. Indeed we 
have shown that CaMK II activation decreased HDAC5 nuclear content (Figure 6.1), which would 
conceivably give rise to the observed increase in HAT activity. Although the HAT concerned has not 
been identified, it has been reported that CaMK II directly phosphorylates and activates p300 (239), a 
HAT that acetylates all four histones and most non histone proteins (14; 23). Acetylation of histones 
relaxes chromatin thereby enhancing access of transcriptional factors and RNA polymerases to the 
DNA site to increase gene transcription. Hyperacetylated histones ensure super induction of genes 
because they have increased ability to interact with transcriptional factors and to anchor 
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transcriptional coactivator complexes to gene promoters (217; 224). For example, hyperacetylated 
histones surrounding the MEF2 site on myogenic genes, such as MyoD, result in increased 
myogenesis in C2 cells (143). In contrast, accumulation of HDAC5 in the nucleus suppresses MEF2 
dependent glut4 promoter activity (214). Czybryt et al (40) confirmed this by showing that HDAC5 
which constitutively localizes in the nucleus result in ~3-fold down-regulation of GLUT4 expression. 
It appears that nuclear HDAC5 forms a complex with MEF2 and deters MEF2-dependent 
transcription (158; 214).  
MEF2A binding to the glut4 was increased ~2-fold with caffeine treatment but the increase 
was blocked by inclusion of KN93; indicating that CaMK II also plays a role in MEF2A binding to 
the glut4 gene. The increase in binding, which correlated with induced hyperacetylation at the same 
DNA site, could have been a consequence of increased accessibility of DNA to transcriptional 
factors. It could also have been due to acetylation of MEF2 because there are reports which indicate 
that p300 acetylates MEF2 factors and increases their DNA binding activity (5; 147; 198). Further 
studies are needed to ascertain which of those factors was responsible for the observed increased 
binding.  
Because
 
caffeine was able to increase GLUT4 expression by ~2.7-fold in this present study,
 
it 
is reasonable to assume that it activates both binding and trans-activation
 
domains of MEF2A. 
Although, the mechanism by which caffeine increased
 
MEF2A trans-activation remains to be 
explored, it appears to activate other downstream kinases, including MAP kinases p38, which are 
known to activate MEF2 trans-activation domain (187; 233-235; 242). Further studies of the role of 
caffeine in MEF2A trans-activation are warranted.   
In summary, we propose the following mechanisms to explain how CaMK activation 
increases GLUT4 expression in C2C12:  CaMK II activation induces nuclear export of HDAC5 
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which increased nuclear HATs activity, resulting in hyperacetylation of histones on sections of the 
glut4 promoter. Hyperacetylation of histones in the vicinity of MEF2 binding domain on the glut4 
promoter increases the accessibility of the domain to MEF2A transcription factors resulting in 
enhanced binding and transcriptional activity of MEF2A.  
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CHAPTER 7 
Summary of the main findings, probable mechanisms and potential avenues for future research 
 
The studies reported in this thesis investigated the molecular mechanisms by which GLUT4 
expression is regulated by NRF-1 and CaMK II in C2C12 myotubes. The studies are important 
because knowledge of the molecular mechanisms involved could reveal targets for new therapeutic 
modalities for type II diabetes, a disease condition which can be prevented or treated by increasing 
GLUT4 expression. The studies showed that NRF-1 increases GLUT4 expression via a cascade 
involving NRF-1→mef2a→MEF2A→glut4→GLUT4; i.e NRF-1 binds to the mef2a gene and 
increases MEF2A expression, and MEF2A in turn binds to the glut4 gene and increases its 
expression. Consistent with our observations, others have shown that NRF-1 overexpression 
significantly increased MEF2A mRNA (185) and protein expression (10). The importance of MEF2A 
in the cascade was demonstrated when it was shown that silencing MEF2A expression in NRF-1 
overexpressing cells resulted in significant reduction in GLUT4 protein expression. It had previously 
been reported that MEF2A expression is increased by CaMK II activation (173). We have now 
shown that CaMK II activation by caffeine: a) increases NRF-1 binding to the mef2a gene in C2C12 
myotubes, b) induces hyperacetylation of histones in the vicinity of the NRF-1 binding site on the 
mef2a gene, c) causes nuclear export of HDAC5, d) increases MEF2A expression, and e) results in 
GLUT4 expression. All the above changes were significantly reduced when KN93 was included in 
the medium together with caffeine, indicating that CaMK II was involved in these processes. 
Collectively, the results from this thesis support the hypothesis that NRF-1 increases GLUT4 
expression via MEF2A and CaMK II activation facilitates these processes.  
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The increases in mef2a-bound NRF-1 and glut4-bound MEF2A that were reported in this 
thesis may have resulted from one or more of the following factors: a) increased abundance of NRF-1 
and MEF2A (8; 94; 112; 135), b) increased accessibility of their binding domains on glut4 and mef2a 
genes, respectively (128; 130; 132; 168), and c) increased binding activity of NRF-1 and MEF2A. 
Once synthesized in the cytosol, MEF2A and NRF-1 transcription factors translocate to the nucleus 
because they possess nuclear localization sequences on their N-terminal domains (20; 200). Increased 
expression, therefore, improves the probability of their interaction with cis elements on DNA of 
target genes. Once bound, the transcription factors recruit other gene regulators, including PGC-1 
(40; 80; 160; 234), which in turn recruits general transcription factors such as transcription factor D 
(TFIID) that are required by RNA pol II, and HATs such as p300/CBP (183) and P/CAF (70; 190) 
which acetylate neighbouring histone tails. These acetylated histones attract and tether to more 
HATs, i.e. p300/CBP, p/CAF or GCN5, via bromodomain within the HATs (111; 113; 175; 217; 
221). The interaction between acetylated histones and these HATs may results in: a) acetylation of 
more neighbouring histone tails and increased binding of more transcription factors through increased 
accessibility of binding sites, and b) acetylation of MEF2A and NRF-1 to increase their binding 
activity. In support of the latter mechanism, Izumi et al., (110) showed that NRF-1 binding is 
increased by P/CAF acetylation. Others have also shown that MEF2 binding to DNA is increased by 
p300/CBP (5; 147). In light of these observations, we envison that the increases in mef2a-bound 
NRF-1 and glut4-bound MEF2A may have been initiated by the increased abundance of NRF-1 and 
MEF2A, respectively, but the robust increases in binding that was observed may have been sustained 
by: a) increases in the abundance of transcription factors and accessibility of elements, and b) 
increased binding activities of MEF2A and NRF-1 due to acetylation. However, assessment of these 
mechanisms was beyond the scope of this thesis. Future studies should: a) assess the accessibility 
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DNA binding sites of these transcription factors to see if this correlates with the increased binding 
and transcription, b) identify the HATs responsible for the observed acetylation of histones, and c) 
characterize the  transcription coactivators that may be recruited by NRF-1 and MEF2A transcription 
factors.  
We found that overexpression of NRF-1 induced a large increase in NRF-1 binding to mef2a 
and δalas genes but relatively small increases in MEF2A and δALAS proteins (Figure 4.3). Similar 
findings have been reported previously: For example, Baar et al., (10), found that there was ~10-fold 
higher binding of NRF-1 to target genes in transgenic mice (compared to wild-type mice) but < 2-
fold higher contents of cytochrome c, δALAS, MEF2A and GLUT4 proteins. In contrast, exercise or 
caffeine causes comparable increases in promoter-bound NRF-1 and the corresponding protein:  For 
example, there was ~1.9-fold increase in NRF-1 binding to δalas promoter in L6 myotubes that were 
treated with caffeine and a corresponding ~2-fold increase in δALAS protein (172). In rats, δalas-
bound NRF-1 and δALAS were both increased ~1.5 fold with exercise (11). The reason for the 
discrepancy between the magnitude of NRF-1 binding and gene expression in NRF-1 overexpression 
studies is not clear. We speculate that all the signals that are essential for gene expression might not 
have been activated sufficiently by NRF-1 overexpression. For example, protein kinases, such as 
AMPK, which phosphorylate the transactivational domain of NRF-1 and increase its transcriptional 
activity (16; 77), may not have been fully activated by NRF-1 overexpression. On the other hand, 
exercise or caffeine triggers a multitude of signals which may account for the coordinated increases 
in binding and transcriptional activities of NRF-1 (94; 115; 116).  
Several studies have reported down regulation of mef2a, glut4 and nrf-1 genes in individuals 
with type II diabetes (161; 177; 180). The findings from this study, which show that increasing the 
expression of NRF-1 also increases mef2a and glut4 expression, suggest that chemicals, such as 
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isoflavines (Genistein) that target the nrf-1 gene and increase its expression (88), might also improve 
the expression of mef2a and glut4 genes and enhance glucose transport capacity. Moreover, such 
drugs may also increase mitochondrial biogenesis since NRF-1 drives the expression of many 
mitochondrial proteins; thus improving lipid oxidation and insulin sensitivity (127). Therefore future 
studies of anti-diabetic drugs that target the nrf-1 gene are warranted. We also observed that CaMK II 
activation increased the expression of both mitochondrial and GLUT4 proteins; suggesting that 
CaMK may also be a worthwhile candidate target for drug modalities to alleviate type II diabetes and 
insulin resistance. Therefore chemicals such as carbachol (12) or histamine (135) which activate 
CaMK II should be investigated to see if they might increase both GLUT4 and mitochondrial proteins 
and alleviate symptoms of type II diabetes.  In conclusion, this thesis has confirmed that NRF-1 
overexpression increases GLUT4 expression and has shown that this effect occurs via the mef2a 
gene. It provides evidence for a transcriptional cascade involving NRF-
1→mef2a→MEF2A→glut4→GLUT4. The thesis has also shown that CaMK activation increases 
GLUT4 expression by a process that involves histone hyperacetylation in the vicinity of the NRF-1 
binding domain on the mef2a gene. These findings were observed in a cell culture model and further 
studies need to be conducted in animal models to confirm them. 
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